# Phage therapy research directory

AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. [Suggest a correction](https://phage.directory/tips).

Latest entry review: 2026-10-05. 96 studies/protocols, 139 centers/companies/access entries and 273 exact registered site groups. Per-entry dates below.

AI-assisted source collection and extraction; registry identity, source/status and duplicate checks. Linked protocol years are not clinic operating dates. Public intake may be unconfirmed for case-by-case programs. Coverage and source access are incomplete; failed retrieval is not evidence of closure.

| Entry | Country | Type | Brief status | Study years | Checked | Sources | Permalink |
|---|---|---|---|---|---|---|---|
| INLAIN UNL-CONICET phage research | Argentina | Research | Research/development | — | 2026-10-03 | [1](https://santafe.conicet.gov.ar/superbacterias/) | [Permanent link](https://phage.directory/items/inlain-unl-conicet-phage-research-88eeaf4c7d035f17aeef0c3fee8ba8c9) |
| Monash Health — Clayton | Australia | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Monash University Phage Foundry | Australia | Supplier | Intake unconfirmed | — | 2026-10-03 | [1](https://www.monash.edu/impact-amr/phage-therapy) [2](https://www.monash.edu/news/articles/scientists-develop-a-virus-cocktail-to-combat-superbugs) | [Permanent link](https://phage.directory/items/monash-university-phage-foundry-dc72420544b95cbe99cc1b03f9eaf2c7) |
| Phage Australia | Australia | Network | Case-by-case; Official referral/inquiry route | — | 2026-10-03 | [1](https://www.phageaustralia.org/patient-information) [2](https://www.phageaustralia.org/our-approach) [3](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382817&isReview=true) | [Permanent link](https://phage.directory/items/phage-australia-dd8ee65eadae5715bde672927bf40a2d) |
| Phage WA / Wal-yan Respiratory Research Centre, The Kids Research Institute Australia | Australia | Network | Official referral/inquiry route | — | 2026-10-03 | [1](https://walyanrespiratory.thekids.org.au/projects/phage-wa/) [2](https://walyanrespiratory.thekids.org.au/projects/phage-wa/phage-therapy-compassionate-use/) [3](https://walyanrespiratory.thekids.org.au/projects/phage-wa/get-involved/) | [Permanent link](https://phage.directory/items/phage-wa-wal-yan-respiratory-research-centre-the-kids-research-institute-australia-7459f355ce2b57748d0e3a6ef2fd2b09) |
| Royal Adelaide Hospital — Adelaide | Australia | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Royal Melbourne Hospital — Melbourne | Australia | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Special Phage Holdings Pty Ltd | Australia | Company | Acquired by AmpliPhi in 2012 | — | 2026-10-03 | [1](https://www.sec.gov/Archives/edgar/data/921114/000155837020002943/armp-20191231x10k.htm) | [Permanent link](https://phage.directory/items/special-phage-holdings-pty-ltd-3bcaf0f330a65e719b266c2b0e68a4c5) |
| STAMP (ACTRN12621001526864) | Australia | Trial | Recruiting | 2022–2027 (estimated) | 2026-10-03 | [1](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382817&isReview=true) | [Permanent link](https://phage.directory/items/stamp-d4644a200f9f5293bf0ab88d19f3ecdd) |
| The Alfred Hospital — Melbourne | Australia | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| VICPhage Service, The Alfred | Australia | Center | Official referral/inquiry route | — | 2026-10-03 | [1](https://www.alfredhealth.org.au/the-alfred/services/hp/vicphage-service) [2](https://www.alfredhealth.org.au/images/resources/referral-forms/Referral_to_Infectious_Diseases_-_VICPhage.pdf) | [Permanent link](https://phage.directory/items/vicphage-service-the-alfred-2ba7d68c4616565eaee130ca655821d1) |
| Westmead Hospital — Westmead | Australia | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Westmead Hospital / Westmead Institute for Medical Research phage team | Australia | Center | Official referral/inquiry route | — | 2026-10-03 | [1](https://wimr.org.au/research-groups/phage-therapy-group/) [2](https://www.phageaustralia.org/patient-information) [3](https://www.phageaustralia.org/our-approach) [4](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382817&isReview=true) [5](https://www.abc.net.au/news/2021-01-15/antibiotic-resistant-superbug-bacteriophage-therapy/12213010) | [Permanent link](https://phage.directory/items/westmead-hospital-westmead-institute-for-medical-research-phage-team-2bfadb04d238566fb61b6387c1d886e0) |
| diSArm (NCT05184764) | Australia; United States | Trial | Completed | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | [Permanent link](https://phage.directory/items/study-evaluating-safety-tolerability-and-efficacy-of-intravenous-ap-sa02-in-subjects-with-b865f812faac5582bec8fd5513490aa5) |
| Former PhagoMed / BioNTech R&D Austria | Austria | Company | Historical/inactive | — | 2026-10-03 | [1](https://investors.biontech.de/system/files-encrypted/nasdaq_kms/assets/2021/11/10/4-05-39/BNTX_Q3%202021%20Presentation_11.09.2021_F.pdf) [2](https://www.biontech.com/content/dam/corporate/pdf/20-F%202023.pdf) | [Permanent link](https://phage.directory/items/former-phagomed-biontech-r-d-austria-13006149511e524c94314c12c29bf5cd) |
| Antibacterial Treatment Against Diarrhea in Oral Rehydration Solution (NCT00937274) | Bangladesh | Trial | Terminated | 2009–2013 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT00937274) | [Permanent link](https://phage.directory/items/antibacterial-treatment-against-diarrhea-in-oral-rehydration-solution-05e6365885b855c1994b21fa47f885d0) |
| Clinical Sciences Division, ICDDR,B, Mohakhali, — Dhaka | Bangladesh | Trial site | Historical trial site | 2009–2013 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT00937274) | — |
| icddr,b | Bangladesh | Research | Historical/inactive | — | 2026-10-03 | [1](https://www.icddrb.org/storage/file/Document/icddr%2Cb%20Annual%20Report_2016_31May17.pdf) | [Permanent link](https://phage.directory/items/icddr-b-126e2a10128455618f2438d57e8018db) |
| CHU Sart-Tilman — Liège | Belgium | Trial site | Historical trial site | 2015–2017 | 2026-10-04 | [1](https://clinicaltrials.gov/study/NCT02116010) | — |
| EPHICACI (NCT06368388) | Belgium | Observational study | Recruiting | 2021–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06368388) | [Permanent link](https://phage.directory/items/establishing-personalized-phage-therapy-and-its-comparative-cost-in-difficult-to-treat-inf-b10b9710e25b532db1e6cddece41d005) |
| Hopital Militaire Reine Astrid — Brussels | Belgium | Trial site | Historical trial site | 2015–2017 | 2026-10-04 | [1](https://clinicaltrials.gov/study/NCT02116010) | — |
| Queen Astrid Military Hospital LabMCT | Belgium | Supplier | Active program; intake unconfirmed | — | 2026-10-03 | [1](https://www.hopitalmilitaire.be/onderzoek_labmct_fr.php) [2](https://www.mil.be/fr/news/la-recherche-medicale-militaire-au-service-de-tous/) [3](https://researchportal.rma.ac.be/de/projects/research-in-support-of-personalized-bacteriophage-therapy-of-diff/) | [Permanent link](https://phage.directory/items/queen-astrid-military-hospital-labmct-d885ecb9e6f6583fac68112ba92c4ee3) |
| University Hospitals Leuven — Leuven | Belgium | Trial site | Recruiting (trial) | 2021–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06368388) | — |
| UZ Leuven Center for Bacteriophage Therapy | Belgium | Center | Official referral/inquiry route | — | 2026-10-03 | [1](https://www.uzleuven.be/en/bacteriophage-therapy) [2](https://clinicaltrials.gov/study/NCT06368388) [3](https://research.kuleuven.be/portal/en/project/3M250516) | [Permanent link](https://phage.directory/items/uz-leuven-center-for-bacteriophage-therapy-f801bf91882d59dcb89312e630245938) |
| PHAGOBURN (NCT02116010) | Belgium; Switzerland; France | Trial | Ended | 2015–2017 | 2026-10-04 | [1](https://clinicaltrials.gov/study/NCT02116010) [2](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000714-65/results) | [Permanent link](https://phage.directory/items/evaluation-of-phage-therapy-for-the-treatment-of-escherichia-coli-and-pseudomonas-aerugino-785d1db7e2395f5b8a10f80de329802e) |
| PhagoBurn consortium | Belgium; Switzerland; France | Research | Historical/inactive | — | 2026-10-03 | [1](https://cordis.europa.eu/project/id/601857) [2](https://clinicaltrials.gov/study/NCT02116010) | [Permanent link](https://phage.directory/items/phagoburn-consortium-d91b6594c61850fdbb73f478c91a9d14) |
| KIDNAP / UNIFESP KPC decolonization (RBR-9f3whw9) | Brazil | Trial | Not yet recruiting | Started 2025 (estimated) | 2026-10-03 | [1](https://ensaiosclinicos.gov.br/rg/RBR-9f3whw9) | [Permanent link](https://phage.directory/items/kidnap-unifesp-kpc-decolonization-e9ccb59bee8752b29b2c57439bbfb424) |
| UNIFESP Escola Paulista de Medicina — KIDNAP | Brazil | Center | Research/development | — | 2026-10-03 | [1](https://ensaiosclinicos.gov.br/rg/RBR-9f3whw9) | [Permanent link](https://phage.directory/items/unifesp-escola-paulista-de-medicina-kidnap-27a2dfcee3d55fc8a46aac538a25e347) |
| University of São Paulo CEPID B3 phage research | Brazil | Research | Research/development | — | 2026-10-03 | [1](https://jornal.usp.br/ciencias/virus-podera-ser-usado-em-tratamento-contra-bacteria-que-causa-infeccoes-hospitalares/) | [Permanent link](https://phage.directory/items/university-of-sao-paulo-cepid-b3-phage-research-e2427ba8e556550ca6e7f3c70bbfb92c) |
| Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa (NCT06798168) | Canada | Individual-case protocol | Expanded access | Not listed | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06798168) | [Permanent link](https://phage.directory/items/bacteriophage-clinical-trial-for-periprosthetic-joint-infection-of-multidrug-resistant-pse-bac9b81dd8ef5f8ca79cbf416a2184db) |
| Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection (NCT07228702) | Canada | Individual-case protocol | Invitation only | 2026–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07228702) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-for-mycobacterium-abscessus-pulmonary-infection-98f2bb10c88657aba36c2ad46d0f8019) |
| Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection (NCT07461337) | Canada | Individual-case protocol | Not yet recruiting | 2026 (estimated)–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07461337) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-for-staphylococcus-lugdunensis-prosthetic-joint-infection-7577f4e771075ae2862bf14741ffaef6) |
| BPhage (NCT06827041) | Canada | Individual-case protocol | Active, not recruiting | 2024–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06827041) | [Permanent link](https://phage.directory/items/use-of-phage-therapy-for-treatment-of-a-periprosthetic-joint-infection-fd162f73d13750ada1aee2926ca6cd08) |
| Concordia Hospital — Winnipeg, Manitoba | Canada | Trial site | Not yet recruiting (trial) | 2025 (estimated)–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06942624) | — |
| Cytophage Technologies | Canada | Company | Intake unconfirmed | — | 2026-10-03 | [1](https://cytophage.com/news/cytophage-identifies-two-new-patient-candidates-for-phage-therapy-for-prosthetic-joint-infections/) | [Permanent link](https://phage.directory/items/cytophage-technologies-7aec9606632a563db9566b6bf6c955a5) |
| DePHEAT-PJI (NCT07698002) | Canada | Trial | Not yet recruiting | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07698002) | [Permanent link](https://phage.directory/items/debridement-phage-antibiotics-for-pji-a208da7825c0595bb7eecaae1ff82c07) |
| Foothills Medical Centre, University of Calgary — Calgary | Canada | Trial site | Mixed trial statuses | 2025–2026 (estimated); 2026 (estimated)–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06814756) [2](https://clinicaltrials.gov/study/NCT07461337) | — |
| McGill University — Corinne Maurice phage research | Canada | Research | Research/development | — | 2026-10-03 | [1](https://www.mcgill.ca/newsroom/corinne-maurice) | [Permanent link](https://phage.directory/items/mcgill-university-corinne-maurice-phage-research-d95370810907598ca350c223f24783a6) |
| Ottawa Hospital Research Institute — Ottawa | Canada | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07698002) | — |
| Ottawa Hospital Research Institute — Ottawa, Ontario | Canada | Trial site | Active, not recruiting (trial) | 2024–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06827041) | — |
| Phage Canada | Canada | Network | Provider-listed inquiry route | — | 2026-10-03 | [1](https://www.phagecanada.ca/en/frequently-asked-questions) [2](https://www.phagecanada.ca/en/contact-us) | [Permanent link](https://phage.directory/items/phage-canada-0b22a17c5bcb5187b6e3f44df40b9461) |
| Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection (NCT06942624) | Canada | Individual-case protocol | Not yet recruiting | 2025 (estimated)–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06942624) | [Permanent link](https://phage.directory/items/phage-therapy-for-the-treatment-of-a-chronic-enterococcus-faecium-periprosthetic-joint-inf-fb80a9100c385f318b708a0f32f6744f) |
| Phage Therapy for the Treatment of Urinary Tract Infection (NCT05537519) | Canada | Individual-case protocol | Status unconfirmed | 2023–2024 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05537519) | [Permanent link](https://phage.directory/items/phage-therapy-for-the-treatment-of-urinary-tract-infection-3431b1c66f9f574abaa0987b6db0c9ae) |
| PHAGE-2024-01 (NCT06456424) | Canada | Individual-case protocol | Active, not recruiting | 2024–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06456424) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-for-methicillin-sensitive-staphylococcus-aureus-prosthetic-joint-inf-476efabaf5475ad4a8dbcd589b453f74) |
| PHAGE-MOM-001 (NCT06814756) | Canada | Individual-case protocol | Active, not recruiting | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06814756) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-for-morganella-morganii-prosthetic-joint-infection-a4acacff7ecb5b84888564f4c39f079d) |
| Public Health Agency of Canada / NML PhageSTAR | Canada | Supplier | Intake unconfirmed | — | 2026-10-03 | [1](https://www.canada.ca/en/public-health/corporate/mandate/about-agency/access-information-privacy/info-source-federal-government-employee-information.html) | [Permanent link](https://phage.directory/items/public-health-agency-of-canada-nml-phagestar-b9f4b701dd025ca7958dba304403a4f2) |
| Qeen Biotechnologies | Canada | Supplier | Provider-listed inquiry route | — | 2026-10-04 | [1](https://qeen-bio.com/patient-access/) [2](https://qeen-bio.com/services/) [3](https://qeen-bio.com/) [4](https://unityhealth.to/2026/06/international-trial-using-viruses-to-treat-drug-resistant-infections/) | [Permanent link](https://phage.directory/items/qeen-biotechnologies-2f92d4dae4ed5d4b84cae554b1084208) |
| South Health Campus — Calgary, Alberta | Canada | Trial site | Active, not recruiting (trial) | 2024–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06456424) | — |
| St. Joseph's Health Centre — Toronto, Ontario | Canada | Trial site | Status unconfirmed (trial) | 2023–2024 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05537519) | — |
| The Ottawa Hospital — Ottawa | Canada | Trial site | Expanded access (trial) | Not listed | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06798168) | — |
| The Ottawa Hospital / OHRI implant infection phage research | Canada | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://impact-program.ca/research) [2](https://clinicaltrials.gov/study/NCT06827041) [3](https://clinicaltrials.gov/study/NCT06798168) [4](https://clinicaltrials.gov/study/NCT07698002) | [Permanent link](https://phage.directory/items/the-ottawa-hospital-ohri-implant-infection-phage-research-b6f51a64c4a65524a7bd1fe3bc049379) |
| Unity Health Toronto / St. Joseph's — Greg German | Canada | Center | Provider-listed inquiry route | — | 2026-10-03 | [1](https://unityhealth.to/2026/02/meet-the-researchers-using-viruses-to-treat-patients/) [2](https://www.phagecanada.ca/en/frequently-asked-questions) [3](https://unityhealth.to/2026/06/international-trial-using-viruses-to-treat-drug-resistant-infections/) | [Permanent link](https://phage.directory/items/unity-health-toronto-st-joseph-s-greg-german-9c571274d7275220aa280808ede9179c) |
| Université Laval Félix d'Hérelle Reference Center for Bacterial Viruses | Canada | Supplier | Intake unconfirmed | — | 2026-10-03 | [1](https://www.phage.ulaval.ca/) [2](https://greb.ulaval.ca/services/) | [Permanent link](https://phage.directory/items/universite-laval-felix-d-herelle-reference-center-for-bacterial-viruses-d216881c7bee5b4abd731d6a98261cb3) |
| University of Calgary / Alberta Health Services phage research | Canada | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://engage.ucalgary.ca/Phage_Therapy) [2](https://clinicaltrials.gov/study/NCT06456424) [3](https://clinicaltrials.gov/study/NCT06814756) [4](https://clinicaltrials.gov/study/NCT07461337) | [Permanent link](https://phage.directory/items/university-of-calgary-alberta-health-services-phage-research-adad97d950105b09b1799f6303124d02) |
| University of Toronto bacteriophage therapy research initiative | Canada | Research | Research/development | — | 2026-10-03 | [1](https://lmp.utoronto.ca/bacteriophage-therapy-research) [2](https://www.phagecanada.ca/en/frequently-asked-questions) | [Permanent link](https://phage.directory/items/university-of-toronto-bacteriophage-therapy-research-initiative-8145719525e75869b648697ce78c779e) |
| Vancouver General Hospital Non-Tuberculous Mycobacterial Disease Clinic — Vancouver, British Columbia | Canada | Trial site | Invitation only (trial) | 2026–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07228702) | — |
| COANIQUEM phage research/regulatory development | Chile | Research | Research/development | — | 2026-10-03 | [1](https://www.leylobby.gob.cl/instituciones/AO005/audiencias/2026/799948/952096) | [Permanent link](https://phage.directory/items/coaniquem-phage-research-regulatory-development-d202f194258f5de9a073f7aa4488b9a9) |
| 1st Medical Center of Chinese PLA General Hospital — Beijing | China | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07612605) | — |
| 8th Medical Center of Chinese PLA General Hospital — Beijing | China | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07612605) | — |
| Anhui Medical University First Affiliated Hospital North District / Anhui Public Health Clinical Center | China | Center | Intake unconfirmed | — | 2026-10-04 | [1](https://www.ahsphcc.cn/info/1134/1421.htm) | [Permanent link](https://phage.directory/items/anhui-medical-university-first-affiliated-hospital-north-district-anhui-public-health-clin-0db54d0257465802adc17075b1aa1762) |
| Bacteriophage Therapy for Orthopedic Implant-Associated Infections (NCT07533292) | China | Trial | Not yet recruiting | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07533292) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-for-orthopedic-implant-associated-infections-5f2aecf56bb95e9a8668ce661aaedfd8) |
| Children’s Hospital of Fudan University / 复旦大学附属儿科医院 | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://ch.shmu.edu.cn/main/news/content/pid/19254.html) [2](https://ch.shmu.edu.cn/uploads/file/20250516/1747381309499556.pdf) | [Permanent link](https://phage.directory/items/children-s-hospital-of-fudan-university-bee084c029e05478b76ce2a2983cf4d9) |
| Chinese PLA General Hospital (First and Eighth Medical Centers) | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07612605) | [Permanent link](https://phage.directory/items/chinese-pla-general-hospital-first-and-eighth-medical-centers-fd97ffd594245376bd7e279042c97f7c) |
| Clinical Study of Phage Therapy for Chronic Constipation Efficacy and Safety (NCT05973721) | China | Trial | Status unconfirmed | 2023–2023 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05973721) | [Permanent link](https://phage.directory/items/clinical-study-of-phage-therapy-for-chronic-constipation-efficacy-and-safety-666ac32d44f25026b20c59a8d2517170) |
| CreatiPhage / 创噬纪（上海）生物技术有限公司 | China | Supplier | Intake unconfirmed | — | 2026-10-03 | [1](https://www.cphage.com/phage_therapy_application/) [2](https://www.cphage.com/) [3](https://www.cphage.com/en_pipelines/) | [Permanent link](https://phage.directory/items/creatiphage-7ef8ae889d6655988ba103791587f618) |
| First Affiliated Hospital of Guangzhou Medical University | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07612605) | [Permanent link](https://phage.directory/items/first-affiliated-hospital-of-guangzhou-medical-university-c87daaa4a704589596df4139032fb3ca) |
| First Affiliated Hospital of Guangzhou University of Chinese Medicine | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07612605) | [Permanent link](https://phage.directory/items/first-affiliated-hospital-of-guangzhou-university-of-chinese-medicine-634f5b21e72252c69e98e0d118c5e70e) |
| First Affiliated Hospital of Xi’an Jiaotong University / 西安交通大学第一附属医院 | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07619924) [2](https://www.cphage.com/media_creatiphage/248) | [Permanent link](https://phage.directory/items/first-affiliated-hospital-of-xi-an-jiaotong-university-abe2ae4a7bb2563e8e858ac5b08039b2) |
| General Hospital of Ningxia Medical University / 宁夏医科大学总医院 | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.nxmu.edu.cn/info/1197/9237.htm) | [Permanent link](https://phage.directory/items/general-hospital-of-ningxia-medical-university-d3fa5fd8f2bc5d189bbecc6234031e61) |
| Hainan Provincial People’s Hospital / 海南省人民医院 | China | Research | Research/development | — | 2026-10-03 | [1](https://www.phhp.com.cn/ppxk/tszk/grk.htm) | [Permanent link](https://phage.directory/items/hainan-provincial-people-s-hospital-e8636c765e9b5026b1a297e4762e8ba6) |
| Hubei Jiangxia Laboratory / 湖北江夏实验室 | China | Research | Intake unconfirmed | — | 2026-10-03 | [1](https://wjw.hubei.gov.cn/bmdt/mtjj/mtgz/202605/t20260519_5938919.shtml) | [Permanent link](https://phage.directory/items/hubei-jiangxia-laboratory-c0c95f4157a4513ca0925ad38109ac9b) |
| Jiahui International Hospital / 上海嘉会国际医院 | China | Center | Status unconfirmed | — | 2026-10-03 | [1](https://www.jiahui.com/news/125) [2](https://www.cphage.com/76/190) | [Permanent link](https://phage.directory/items/jiahui-international-hospital-8057736f02285c74a7cfb1644085eedb) |
| Jiahui International Hospital phage study lead (ChiCTR2300067705) | China | Trial lead | Unverified lead | Not listed | 2026-10-03 | [1](https://www.jiahui.com/news/125) | [Permanent link](https://phage.directory/items/jiahui-international-hospital-phage-study-lead-0ed5fd71ab6d5415bdf32dd4f4080c5c) |
| Nanjing Drum Tower Hospital / 南京鼓楼医院 | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.chictr.org.cn/hvshowproject.html?id=301261&v=1.0) | [Permanent link](https://phage.directory/items/nanjing-drum-tower-hospital-06b7cb76b0cf5c8db2bebc251eeaa10f) |
| Nanjing Drum Tower phage pilot (ChiCTR2600124009) | China | Trial | Not yet recruiting | Not listed | 2026-10-03 | [1](https://www.chictr.org.cn/hvshowproject.html?id=301261&v=1.0) | [Permanent link](https://phage.directory/items/nanjing-drum-tower-phage-pilot-9ca43bb4a5b1595ea2287b70bd4508e5) |
| Randomized Controlled Study on the Safety and Efficacy of Phage Cocktail in the Treatment of Multidrug-Resistant Bacterial Skin Infections (NCT07619924) | China | Trial | Invitation only | 2025–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07619924) | [Permanent link](https://phage.directory/items/randomized-controlled-study-on-the-safety-and-efficacy-of-phage-cocktail-in-the-treatment-bf124138fe7c588fbb0f0eceb40ed444) |
| Second Affiliated Hospital, Zhejiang University School of Medicine | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07533292) | [Permanent link](https://phage.directory/items/second-affiliated-hospital-zhejiang-university-school-of-medicine-a2aee1902e6d53aaab13e10e1594545c) |
| Shanghai Public Health Clinical Center / 上海市公共卫生临床中心 | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.chictr.org.cn/hvshowproject.html?id=276909&v=1.0) [2](https://www.shanghai.gov.cn/nw4411/20250823/ff84d819233a404dbaf2fb4f79737435.html) | [Permanent link](https://phage.directory/items/shanghai-public-health-clinical-center-29443d14c5c6558a9672a5c2988d3fb7) |
| Shanghai Public Health Clinical Center personalized phage study (ChiCTR2500102677) | China | Trial | Not yet recruiting | Not listed | 2026-10-03 | [1](https://www.chictr.org.cn/hvshowproject.html?id=276909&v=1.0) | [Permanent link](https://phage.directory/items/shanghai-public-health-clinical-center-personalized-phage-study-fd896b8fcebc559bacbfc5697d844888) |
| Shanghai Tenth People's Hospital — Shanghai | China | Trial site | Status unconfirmed (trial) | 2023–2023 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05973721) | — |
| Shenzhen People’s Hospital / 深圳市人民医院 | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.chictr.org.cn/showproj.html?proj=275896) | [Permanent link](https://phage.directory/items/shenzhen-people-s-hospital-6d3ba7312ae456f2b4dc193b27a2e5f5) |
| Shenzhen People's Hospital ICU pneumonia phage study (ChiCTR2500104137) | China | Trial | Status unconfirmed | Not listed | 2026-10-03 | [1](https://www.chictr.org.cn/showproj.html?proj=275896) | [Permanent link](https://phage.directory/items/shenzhen-people-s-hospital-icu-pneumonia-phage-study-ceebdc91b4f1555ba8aae6de47369bfd) |
| The First Affiliated Hospital of Guangzhou Medical University — Guangdong, Guangzhou | China | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07612605) | — |
| The First Affiliated Hospital of Guangzhou University of Chinese Medicine — Guangdong, Guangzhou | China | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07612605) | — |
| The First Affiliated Hospital of Xi'an Jiaotong University — Xi'an, Shaanxi | China | Trial site | Invitation only (trial) | 2025–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07619924) | — |
| the Second Affiliated Hospital of Zhejiang University School of Medicine — Hangzhou, Zhejiang | China | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07533292) | — |
| Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia (NCT07612605) | China | Trial | Not yet recruiting | 2026 (estimated)–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07612605) | [Permanent link](https://phage.directory/items/yiqi-huoxue-jiedu-formula-combined-with-bacteriophages-in-the-treatment-of-severe-pneumoni-51c2abbbdeb8521698a1f85078c1e9af) |
| Zhongshan Hospital personalized phage pilot (ChiCTR2400082131) | China | Trial | Not yet recruiting | Not listed | 2026-10-03 | [1](https://www.chictr.org.cn/showprojEN.html?proj=223337) | [Permanent link](https://phage.directory/items/zhongshan-hospital-personalized-phage-pilot-9dc6063a7f8d58ee9524d6dfce6e6d96) |
| Zhongshan Hospital, Fudan University / 复旦大学附属中山医院 | China | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.chictr.org.cn/showprojEN.html?proj=223337) | [Permanent link](https://phage.directory/items/zhongshan-hospital-fudan-university-09f8869bb9d35ce784001fa2d6ebdc4c) |
| Pontificia Universidad Javeriana phage research | Colombia | Research | Research/development | — | 2026-10-03 | [1](https://www.javeriana.edu.co/pesquisa/helicobacter-pylori-colombia-tratamiento-antibiotico/) | [Permanent link](https://phage.directory/items/pontificia-universidad-javeriana-phage-research-248c3cee61945ae48f53f788af163b70) |
| Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® (NCT06319235) | Czechia | Trial | Status unconfirmed | 2023–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06319235) | [Permanent link](https://phage.directory/items/clinical-trial-to-demonstrate-the-safety-and-efficacy-of-duofag-3d3491b6745053b0ad32913fd4c5327c) |
| MB Pharma / DUOFAG | Czechia | Company | Research/development | — | 2026-10-03 | [1](https://www.mbph.cz/duofag) [2](https://clinicaltrials.gov/study/NCT06319235) | [Permanent link](https://phage.directory/items/mb-pharma-duofag-e56da8a5218c5fb19c3540137b949482) |
| St. Anne's University Hospital Brno — Brno, Czech Republic | Czechia | Trial site | Status unconfirmed (trial) | 2023–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06319235) | — |
| University Hospital in Motol — Prague | Czechia | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| Study With Phage for CF Subjects With Pseudomonas Lung Infection (NCT06998043) | Czechia; Germany; Spain; France; Ireland; Italy; Netherlands; Poland; United States | Trial | Conflicting status | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06998043) [2](https://euclinicaltrials.eu/ctis-public/view/2024-519856-94-00?lang=en) [3](https://www.sec.gov/Archives/edgar/data/1739174/000121390026078003/ea0298043-424b3_biomx.htm) | [Permanent link](https://phage.directory/items/study-with-phage-for-cf-subjects-with-pseudomonas-lung-infection-3e1370bb949f5ec7a33ffea7e50d6487) |
| Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection (NCT05010577) | Czechia; Spain; Israel; Netherlands; United States | Trial | Completed | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | [Permanent link](https://phage.directory/items/nebulized-bacteriophage-therapy-in-cystic-fibrosis-patients-with-chronic-pseudomonas-aerug-9a04949ae2e65f95a5a01fef55c15796) |
| PrePhage - Faecal Bacteriophage Transfer for Enhanced Gastrointestinal Tract Maturation in Preterm Infants (NCT05272579) | Denmark | Adjacent product trial | Recruiting | 2023–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05272579) | [Permanent link](https://phage.directory/items/prephage-faecal-bacteriophage-transfer-for-enhanced-gastrointestinal-tract-maturation-in-p-10e6d0acef78540b9d554453e2b65dae) |
| Rigshospitalet — Copenhagen | Denmark | Trial site | Recruiting (trial) | 2023–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05272579) | — |
| SNIPR Biome | Denmark | Company | Provider-listed inquiry route | — | 2026-10-03 | [1](https://www.sniprbiome.com/expandedaccess) [2](https://www.sniprbiome.com/) [3](https://clinicaltrials.gov/study/NCT06938867) [4](https://clinicaltrials.gov/study/NCT05277350) | [Permanent link](https://phage.directory/items/snipr-biome-f660ac748a965d4c9e1f9a0f7608737f) |
| HUS / University of Helsinki phage therapy collaboration | Finland | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.hus.fi/sv/aktuellt/bakteriofager-som-losning-pa-antibiotikaresistens) [2](https://www.helsinki.fi/en/researchgroups/phage-therapy) [3](https://www.helsinki.fi/en/researchgroups/phage-therapy/people) | [Permanent link](https://phage.directory/items/hus-university-of-helsinki-phage-therapy-collaboration-e49c3906957b51e2862be8f171053ad0) |
| AP-HP / PYOPHANEB multicenter study | France | Network | Intake unconfirmed | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | [Permanent link](https://phage.directory/items/ap-hp-pyophaneb-multicenter-study-966ba8b11197512bb2c89b0b10f36dd4) |
| Avis-PHAGEinLYON Clinic (NCT05883995) | France | Observational study | Recruiting | 2023–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05883995) | [Permanent link](https://phage.directory/items/avis-phageinlyon-clinic-73b2242d86be5e7c9c503f13607edd97) |
| Centre de Référence des Infections Ostéo-Articulaires complexes (CRIOAc) - Hôpital de la Croix-Rousse — Lyon | France | Trial site | Recruiting (trial) | 2023–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05883995) | — |
| Centre hospitalier ST Joseph et St Luc — Lyon | France | Trial site | Historical trial site | 2015–2017 | 2026-10-04 | [1](https://clinicaltrials.gov/study/NCT02116010) | — |
| CH de Tourcoing — Tourcoing | France | Trial site | Conflicting status (trial) | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT02664740) | — |
| CH Intercommunal de Villeneuve-Saint-Georges — Villeneuve-Saint-Georges | France | Trial site | Conflicting status (trial) | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT02664740) | — |
| CH Nantes — Nantes | France | Trial site | Historical trial site | 2024 (estimated)–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06370598) | — |
| CHRU de Nîmes - Hôpital Universitaire de Réadaptation du Grau du Roi — Le Grau-du-Roi | France | Trial site | Conflicting status (trial) | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT02664740) | — |
| CHRU de Toulouse - Hôpital de Rangueil — Toulouse | France | Trial site | Conflicting status (trial) | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT02664740) | — |
| CHU Amiens — Amiens | France | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | — |
| CHU Angers — Angers | France | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | — |
| CHU Clermont-Ferrand — Clermont-Ferrand | France | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | — |
| CHU de Bordeaux - Hôpital Pellegrin — Bordeaux | France | Trial site | Conflicting status (trial) | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT02664740) | — |
| CHU Nice — Nice | France | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | — |
| CHU Nîmes / PhagoPied multicenter study | France | Network | Intake unconfirmed | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT02664740) [2](https://euclinicaltrials.eu/ctis-public/view/2022-500541-24-00?lang=en) | [Permanent link](https://phage.directory/items/chu-nimes-phagopied-multicenter-study-a6ca51ab48b55f8cb6ca0f4f0f40d9ee) |
| CHU Orléans — Orléans | France | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | — |
| Department of Infectious and Tropical Diseases of the Croix Rousse Hospital of the Civil Hospitals of Lyon — Lyon | France | Trial site | Recruiting (trial) | 2023–2034 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06185920) | — |
| Eligo Bioscience | France | Company | Research/development | — | 2026-10-03 | [1](https://eligo.bio/) [2](https://eligo.bio/gsk-deal/) | [Permanent link](https://phage.directory/items/eligo-bioscience-3eccd2a42ba65cd7b5e865840e85349f) |
| Hôpital Avicenne — Bobigny | France | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | — |
| Hôpital Bicêtre — Le Kremlin-Bicêtre | France | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | — |
| Hôpital d'instruction des armées Percy — Clamart | France | Trial site | Historical trial site | 2015–2017 | 2026-10-04 | [1](https://clinicaltrials.gov/study/NCT02116010) | — |
| Hopital européen — Marseille | France | Trial site | Conflicting status (trial) | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT02664740) | — |
| Hôpital Henri Mondor — Créteil | France | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | — |
| Hôpital Louis Mourier — Colombes | France | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | — |
| Hôpital Pitié-Salpêtrière — Paris | France | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | — |
| Hospices Civils de Lyon — Lyon | France | Trial site | Mixed trial statuses | 2022–2028 (estimated); 2021–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04650607) [2](https://clinicaltrials.gov/study/NCT04724603) | — |
| Hospices Civils de Lyon / CRIOAc / PHAGEinLYON | France | Center | Official referral/inquiry route | — | 2026-10-04 | [1](https://www.chu-lyon.fr/phagotherapie-bacteriophage) [2](https://www.chu-lyon.fr/autorisation-production-phages-therapeutiques) [3](https://recherche.chu-lyon.fr/plateforme-des-phages-therapeutiques) | [Permanent link](https://phage.directory/items/hospices-civils-de-lyon-crioac-phageinlyon-1a790c707e8c53f6a8e7e431dba2c250) |
| PHA-SA-CO (NCT04650607) | France | Observational study | Recruiting | 2022–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04650607) | [Permanent link](https://phage.directory/items/phage-safety-cohort-study-c543a266f0145770881a081c4164f64b) |
| PHAGEinLYON Clinic Cohort Study: a Descriptive Study of Severe Infections Treated With Phage Therapy at the HCL. (NCT06185920) | France | Observational study | Recruiting | 2023–2034 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06185920) | [Permanent link](https://phage.directory/items/phageinlyon-clinic-cohort-study-a-descriptive-study-of-severe-infections-treated-with-phag-d7b7685136225d38b6fa3671679265de) |
| PHAGENIX | France | Company | Research/development | — | 2026-10-03 | [1](https://phagenix.com/en/mission-history/) [2](https://phagenix.com/en/contact-en/) [3](https://clinicaltrials.gov/study/NCT06605651) [4](https://euclinicaltrials.eu/ctis-public/view/2024-516555-40-00?lang=en) [5](https://euclinicaltrials.eu/ctis-public/view/2024-516207-17-00?lang=en) | [Permanent link](https://phage.directory/items/phagenix-48d318d6a1065d9b9e75d371a2288d79) |
| PhagoDAIRI (NCT05369104) | France | Trial | Ended | 2022–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05369104) [2](https://euclinicaltrials.eu/ctis-public/view/2024-516207-17-00?lang=en) | [Permanent link](https://phage.directory/items/phage-therapy-in-prosthetic-joint-infection-due-to-staphylococcus-aureus-treated-with-dair-2cfa70711cdd524fa06501fa6e8a864d) |
| PhagoPied (NCT02664740) | France | Trial | Conflicting status | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT02664740) [2](https://euclinicaltrials.eu/ctis-public/view/2022-500541-24-00?lang=en) | [Permanent link](https://phage.directory/items/standard-treatment-associated-with-phage-therapy-versus-placebo-for-diabetic-foot-ulcers-i-97caac1775e7551e821f2388b79466b6) |
| PHASACO-retro (NCT04724603) | France | Observational study | Status unconfirmed | 2021–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04724603) | [Permanent link](https://phage.directory/items/phage-safety-retrospective-cohort-study-256c46ec866f53eaa7e211ff1013c835) |
| PHAXIAM Therapeutics / former Pherecydes pipeline | France | Company | Historical/inactive | — | 2026-10-03 | [1](https://live.euronext.com/fr/products/equities/company-news/2025-06-12-phaxiam-therapeutics-annonce-sa-liquidation-judiciaire-et) [2](https://phagenix.com/en/phaxiam-therapeutics-announces-judicial-liquidation-and-delisting/) [3](https://cordis.europa.eu/project/id/601857) | [Permanent link](https://phage.directory/items/phaxiam-therapeutics-former-pherecydes-pipeline-02030a857d2d5a1987b3f078611e62e1) |
| Pr Tristan Ferry — Lyon | France | Trial site | Historical trial site | 2022–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05369104) | — |
| PYOPHANEB (NCT07804082) | France | Trial | Not yet recruiting | 2026 (estimated)–2030 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07804082) | [Permanent link](https://phage.directory/items/a-double-blind-placebo-controlled-study-of-nebulized-bacteriophages-in-patients-with-venti-9fb9ae0a065a52689020e71b8979fae4) |
| RECOVER (NCT06370598) | France | Trial | Not authorised | 2024 (estimated)–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06370598) [2](https://euclinicaltrials.eu/ctis-public/view/2023-508825-29-00?lang=en) | [Permanent link](https://phage.directory/items/phase-1-2a-to-assess-the-safety-and-tolerability-of-tp-122a-for-the-treatment-of-ventilato-afae7557df685595a0a22281cb836f57) |
| Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate (NCT03140085) | Georgia | Trial | Completed | 2017–2018 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT03140085) | [Permanent link](https://phage.directory/items/bacteriophages-for-treating-urinary-tract-infections-in-patients-undergoing-transurethral-0e5331f1a7b0590e9843dc9afbc9b6b5) |
| BioChimPharm | Georgia | Supplier | Provider-listed inquiry route | — | 2026-10-03 | [1](https://biochimpharm.ge/en/) [2](https://biochimpharm.ge/en/news/biochimpharm-renovates-the-worlds-oldest-phage-factory/) | [Permanent link](https://phage.directory/items/biochimpharm-15d1de369b355e0fb23f1ed4e6a20f30) |
| Eliava BioPreparations | Georgia | Supplier | Provider-listed inquiry route | — | 2026-10-03 | [1](https://phage.ge/en/about/1) [2](https://phage.ge/en/contact) | [Permanent link](https://phage.directory/items/eliava-biopreparations-da7e9a6082b2584b83fd11b658b42f63) |
| Eliava Phage Therapy Center (EPTC) | Georgia | Center | Provider-listed inquiry route | — | 2026-10-05 | [1](https://eptc.ge/) [2](https://eptc.ge/contact/) | [Permanent link](https://phage.directory/items/eliava-phage-therapy-center-eptc-ee64767f2ce65d3bad9942b23dce07c9) |
| George Eliava Institute of Bacteriophages, Microbiology and Virology | Georgia | Research | Research/development | — | 2026-10-03 | [1](https://eliava-institute.org/en) [2](https://eliava-institute.org/en/about-us) | [Permanent link](https://phage.directory/items/george-eliava-institute-of-bacteriophages-microbiology-and-virology-731f51539c315b8c936b5bec2da3b361) |
| National Center of Urology — Tbilisi | Georgia | Trial site | Historical trial site | 2017–2018 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT03140085) | — |
| Phage Therapy Center LTD, Tbilisi | Georgia | Center | Provider-listed inquiry route | — | 2026-10-05 | [1](https://www.phagetherapycenter.com/pii/PatientServlet?command=responsive_medsvcs) [2](https://www.phagetherapycenter.com/pii/PatientServlet?command=responsive_treatoverview) [3](https://www.phagetherapycenter.com/pii/PatientServlet?command=responsive_ourhistory) [4](https://www.phagetherapycenter.com/pii/PatientServlet?command=responsive_home) [5](https://www.phagetherapycenter.com/pii/PatientServlet?command=responsive_contact) [6](https://www.phagetherapycenter.com/pii/PatientServlet?command=responsive_createuserid) | [Permanent link](https://phage.directory/items/phage-therapy-center-ltd-tbilisi-933789efb38555be9730d0563ad0b786) |
| BG Klinikum Bergmannstrost Halle / Institute for Phage Medicine | Germany | Center | Case-by-case; Official referral/inquiry route | — | 2026-10-04 | [1](https://www.bg-kliniken.de/klinikum-bergmannstrost-halle/fachbereiche/detail/septische-und-rekonstruktive-chirurgie/) [2](https://www.bg-kliniken.de/mvz-bergmannstrost-halle/ueber-uns/klinikum-blaupause/aktuelles/pressemitteilungen/detail/bergmannstrost-gruendet-institut-fuer-phagenmedizin-neue-perspektiven-im-kampf-gegen-multiresistente-erreger/) | [Permanent link](https://phage.directory/items/bg-klinikum-bergmannstrost-halle-institute-for-phage-medicine-9de167d9ba9959fd905e9bc0d6ad5a17) |
| Bundeswehr Hospital Berlin / PhagoFlow | Germany | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://innovationsfonds.g-ba.de/downloads/beschluss-dokumente/877/2025-06-20_PTmHBP.pdf) | [Permanent link](https://phage.directory/items/bundeswehr-hospital-berlin-phagoflow-477f62de610a5430bae562e0cd63a8ca) |
| Charité / Phage4Cure consortium | Germany | Research | Research/development | — | 2026-10-03 | [1](https://phage4cure.de/en/news/) [2](https://phage4cure.de/de/projekt/) | [Permanent link](https://phage.directory/items/charite-phage4cure-consortium-f77bb9ffade95a84972e6d1f8106bfb5) |
| Department of Dermatology — Tübingen | Germany | Trial site | Recruiting (trial) | 2024–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06290557) | — |
| Department of Dermatology, University Hospital Tuebingen — Tübingen | Germany | Trial site | Recruiting (trial) | 2024–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06290557) | — |
| Hannover Medical School clinical phage program | Germany | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.mhh.de/presse-news-detailansicht/die-guten-viren-was-bakteriophagen-leisten-koennen) [2](https://www.balgrist.ch/ueber-uns/medien/mit-viren-gegen-bakterien-eu-foerdert-phagentherapie-mit-15-millionen-euro-1011/) | [Permanent link](https://phage.directory/items/hannover-medical-school-clinical-phage-program-87cc2eac1acb5b36b3cf85b25ebb4481) |
| HY-133 (NCT06290557) | Germany | Adjacent product trial | Recruiting | 2024–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06290557) [2](https://euclinicaltrials.eu/ctis-public/view/2023-507737-17-00?lang=en) | [Permanent link](https://phage.directory/items/first-in-man-single-dose-and-multiple-dose-study-to-evaluate-the-safety-tolerability-and-e-df7243fd91555b2784b698d9bfa518c9) |
| Phage Center Regensburg / University Hospital Regensburg | Germany | Center | Official referral/inquiry route | — | 2026-10-03 | [1](https://phagecenter-regensburg.de/service.html) | [Permanent link](https://phage.directory/items/phage-center-regensburg-university-hospital-regensburg-d84b5894f64f5b1ca7e90bd1881bd9ae) |
| Phage Therapeutics GmbH | Germany | Company | Research/development | — | 2026-10-03 | [1](https://www.phage-therapeutics.bio/en) | [Permanent link](https://phage.directory/items/phage-therapeutics-gmbh-2b3d291a7d2f59ceafa37117fae22d2c) |
| Phage4Cure-001 (2023-507203-55-00) | Germany | Trial | Ended | Not listed | 2026-10-03 | [1](https://euclinicaltrials.eu/ctis-public/view/2023-507203-55-00?lang=en) [2](https://euclinicaltrials.eu/ctis-public/view/2022-503145-22-00?lang=en) | [Permanent link](https://phage.directory/items/phage4cure-001-58516dd05a1255299b2d63daaf6a8a23) |
| Universitätsmedizin Frankfurt phage therapy program | Germany | Center | Official referral/inquiry route | — | 2026-10-03 | [1](https://www.unimedizin-ffm.de/einrichtungen/kliniken/zentrum-der-inneren-medizin/medizinische-klinik-2-haematologie-onkologie-haemostaseologie-rheumatologie-infektiologiehiv/infektiologie/forschung/bacteriophages) | [Permanent link](https://phage.directory/items/universitatsmedizin-frankfurt-phage-therapy-program-204feb52d7435d3d9786571d8c3d46e6) |
| REPhRAME research consortium | Germany; Switzerland; Netherlands; Hungary; Slovenia; Denmark; United Kingdom; Latvia | Network | Research/development | — | 2026-10-04 | [1](https://www.rephrame-project.eu/) | [Permanent link](https://phage.directory/items/rephrame-research-consortium-93010ddd7ac05ca980e0202ae475815a) |
| All India Institute of Medical Sciences, New Delhi | India | Research | Research/development | — | 2026-10-03 | [1](https://pmc.ncbi.nlm.nih.gov/articles/PMC10466484/) | [Permanent link](https://phage.directory/items/all-india-institute-of-medical-sciences-new-delhi-a4354bba330b59268a287d5966350ada) |
| Aman Hospital & Research Centre — Vadodara | India | Trial site | Historical trial site | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) | — |
| Crescent Hospital & Heart Centre — Nagpur | India | Trial site | Historical trial site | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) | — |
| GangaGen Biotechnologies | India | Company | Research/development | — | 2026-10-03 | [1](https://gangagen.com/about.html) [2](https://gangagen.com/Bacteriophages.html) [3](https://gangagen.com/locations.html) | [Permanent link](https://phage.directory/items/gangagen-biotechnologies-10824b7ff1e75ad78427d49ed0bc21aa) |
| GSVM Medical College — Kanpur | India | Trial site | Historical trial site | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) | — |
| Institute of Medical Sciences, Banaras Hindu University / Sir Sunderlal Hospital | India | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://pubmed.ncbi.nlm.nih.gov/42146989/) [2](https://www.bhu.ac.in/Images/files/Minimalist%20Fashion%20Style%20Brochure%20%283%29.pdf) | [Permanent link](https://phage.directory/items/institute-of-medical-sciences-banaras-hindu-university-sir-sunderlal-hospital-5a047c60cf895371b490ed6a16b2156e) |
| Jupiter Hospital & Research Center — Vadodara | India | Trial site | Historical trial site | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) | — |
| MV Hospital for Diabetes Pvt. Ltd — Chennai | India | Trial site | Historical trial site | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) | — |
| Parikh Multispeciality Healthcare Pvt. Ltd — Vadodara | India | Trial site | Historical trial site | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) | — |
| Postgraduate Institute of Medical Education and Research | India | Research | Research/development | — | 2026-10-03 | [1](https://pgimer.edu.in/PGIMER_PORTAL/PGIMERPORTAL/Department/Global/JSP/empview.jsp?id=548) | [Permanent link](https://phage.directory/items/postgraduate-institute-of-medical-education-and-research-4ef0ba003c135ac787cfe011e007fc6a) |
| Shree Siddhi Vinayak Hospital — Nashik | India | Trial site | Historical trial site | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) | — |
| Swastha Phage Solutions Pvt Ltd | India | Company | Research/development | — | 2026-10-03 | [1](https://swastha-phage.com/) | [Permanent link](https://phage.directory/items/swastha-phage-solutions-pvt-ltd-2d0863b541b35832b51ae6081a86960d) |
| Vitalis Phage Therapy | India | Facilitator | Website active; facilitator | — | 2026-10-03 | [1](https://vitalisphagetherapy.com/) [2](https://vitalisphagetherapy.com/our-story/) | [Permanent link](https://phage.directory/items/vitalis-phage-therapy-3fee975eb36f52e5965e5102e23f44a1) |
| Yalamanchi Hospitals & Research Centers Pvt. Ltd — Vijayawada | India | Trial site | Historical trial site | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) | — |
| REVERSE2 (NCT05948592) | India; Poland; United States | Trial | Completed | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) [2](https://euclinicaltrials.eu/ctis-public/view/2023-507716-13-00?lang=en) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-tp-102-in-patients-with-diabetic-foot-infection-1c0cb24cbd715a459ee146337819d2a3) |
| Mazandaran University of Medical Sciences hospital research teams | Iran | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://pubmed.ncbi.nlm.nih.gov/37123173/) [2](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467631/) | [Permanent link](https://phage.directory/items/mazandaran-university-of-medical-sciences-hospital-research-teams-d22047e83e085a0a8100a3f99e4f1590) |
| Nooshin Dalili — Tehran | Iran | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05967130) | — |
| Treatment Chronic UTI Post Kidney Transplant (NCT05967130) | Iran | Trial | Terminated | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05967130) | [Permanent link](https://phage.directory/items/treatment-chronic-uti-post-kidney-transplant-ade14532d75d5889825bf2f084b43bb6) |
| Carmel Medical Center — Haifa | Israel | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| Hadassah Medical Center, Ein Kerem — Jerusalem | Israel | Trial site | Historical trial site | 2021–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04803708) | — |
| Hadassah University Medical Center — Jerusalem | Israel | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| Israeli Phage Therapy Center — Hadassah Medical Center / Hebrew University | Israel | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://international.huji.ac.il/news/huji-and-hadassah-join-%E2%82%AC15-million-euro-phage-uti-trial?ref_tid=20596) [2](https://he.hadassah.org.il/lab/the-israeli-center-for-the-treatment-of-phages/) [3](https://he.hadassah.org.il/medicine-specialization/specialization-in-clinical-microbiology-and-infectious-diseases/) [4](https://pmc.ncbi.nlm.nih.gov/articles/PMC10205549/) | [Permanent link](https://phage.directory/items/israeli-phage-therapy-center-hadassah-medical-center-hebrew-university-659b5d430058548ca1edff9f5fba6be5) |
| Rambam Health Care Campus (RHCC) - Ruth Rappaport Children's Hospital — Haifa | Israel | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| REVERSE (NCT04803708) | Israel | Trial | Completed | 2021–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04803708) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-tp-102-in-diabetic-foot-ulcers-d0f6c4cb92b35ba785498b69649c8e8c) |
| Schneider Children's Medical Center of Israel — Petach Tikvah | Israel | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| Tel Aviv Sourasky Medical Center — Tel Aviv | Israel | Trial site | Historical trial site | 2021–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04803708) | — |
| The Chaim Sheba Medical Center — Ramat Gan | Israel | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| BiomX / former Adaptive Phage Therapeutics (PhageBank) | Israel; United States | Company | Historical/inactive | — | 2026-10-03 | [1](https://www.sec.gov/Archives/edgar/data/1739174/000121390026078003/ea0298043-424b3_biomx.htm) [2](https://clinicaltrials.gov/study/NCT06998043) [3](https://clinicaltrials.gov/study/NCT05269134) [4](https://clinicaltrials.gov/study/NCT04787250) | [Permanent link](https://phage.directory/items/biomx-former-adaptive-phage-therapeutics-phagebank-3cd4540af7035a76b49f7231d24cdeb6) |
| Jichi Medical University, Bacteriology | Japan | Research | Research/development | — | 2026-10-03 | [1](https://www.jichi.ac.jp/bacteriology/en/research.html) [2](https://www.jichi.ac.jp/bacteriology/en/recruit_postdoc.html) | [Permanent link](https://phage.directory/items/jichi-medical-university-bacteriology-8c0d1e4078ef51c7b484f9eb2f25b78b) |
| Osaka Metropolitan University Hospital — acne phage trial | Japan | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://rctportal.mhlw.go.jp/en/detail?trial_id=jRCTs051230164) | [Permanent link](https://phage.directory/items/osaka-metropolitan-university-hospital-acne-phage-trial-58f9688e8742560592eb0a9a7156e2f2) |
| Topical phage gel for acne vulgaris (jRCTs051230164) | Japan | Trial | Not recruiting | Not listed | 2026-10-03 | [1](https://rctportal.mhlw.go.jp/en/detail?trial_id=jRCTs051230164) | [Permanent link](https://phage.directory/items/topical-phage-gel-for-acne-vulgaris-ff2d0e6cd4d85cc0ad38f18011d80f45) |
| University of Osaka, RIMD Fujimoto Laboratory | Japan | Research | Research/development | — | 2026-10-03 | [1](https://www.biken.osaka-u.ac.jp/en/laboratories/detail/73) [2](https://rctportal.mhlw.go.jp/en/detail?trial_id=jRCTs051230164) | [Permanent link](https://phage.directory/items/university-of-osaka-rimd-fujimoto-laboratory-54cc60059f1d56f8a900d3a2dcb13b7c) |
| Waseda University Phage Therapy Institute | Japan | Research | Research/development | — | 2026-10-03 | [1](https://www.waseda.jp/inst/cro/en/institutes-list/phage-therapy-institute/?lng=en) | [Permanent link](https://phage.directory/items/waseda-university-phage-therapy-institute-8e11c1ead43e5bf885b74dfb082b87af) |
| Kenya Institute of Primate Research | Kenya | Research | Research/development | — | 2026-10-03 | [1](https://www.health.go.ke/prioritizing-sustainable-health-solutions-universal-health-coverage) | [Permanent link](https://phage.directory/items/kenya-institute-of-primate-research-3372ed2159ea54f78d5613e60014b45d) |
| Kenya Medical Research Institute | Kenya | Research | Research/development | — | 2026-10-03 | [1](https://www.kemri.go.ke/bacteriophages-phages-to-complement-efforts-to-tackle-antimicrobial-resistance/) [2](https://www.kemri.go.ke/wp-content/uploads/2025/01/KEMRI-RESEARCHER-ISSUE-7-for-web-.pdf) | [Permanent link](https://phage.directory/items/kenya-medical-research-institute-7c1d6fb2275f54ac9c0885953bf87f24) |
| A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli (NCT07338123) | Location not listed | Trial | Not yet recruiting | 2026 (estimated)–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07338123) | [Permanent link](https://phage.directory/items/a-randomized-controlled-trial-rct-of-yiqi-huoxue-jiedu-formula-combined-with-bacteriophage-645704a771425cba921de8279f35bfc7) |
| A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis (NCT05240300) | Location not listed | Trial | Withdrawn | 2022 (estimated)–2023 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05240300) | [Permanent link](https://phage.directory/items/a-study-of-topical-bx005-a-in-subjects-with-moderate-to-severe-atopic-dermatitis-b2b5ad9bae66515099798b254ded6758) |
| ACTIVE1 (NCT05269121) | Location not listed | Trial | Withdrawn | 2022 (estimated)–2024 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269121) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-in-first-time-chronic-prosthetic-joint-infections-009ed71b2d6c54958adf496aea0e9662) |
| Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia (NCT07202234) | Location not listed | Trial | Not yet recruiting | 2025 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07202234) | [Permanent link](https://phage.directory/items/bacteriophage-cocktail-therapy-for-multidrug-resistant-gram-negative-ventilator-associated-19aba276435c58b49abea6c135b44fd1) |
| Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection (NCT07429162) | Location not listed | Individual-case protocol | Not yet recruiting | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07429162) | [Permanent link](https://phage.directory/items/bacteriophage-for-chronic-multidrug-resistant-mycobacterium-abscessus-subsp-abscessus-pulm-ee078d18a3b35540903a50bbb1e62d80) |
| BT100 (NCT05498363) | Location not listed | Observational study | Completed | 2008–2021 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05498363) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-of-difficult-to-treat-infections-1ab42c27eb0a55c7b0ca33f3273eb3a7) |
| Effect of PreforPro® on Urinary and Vaginal Health (NCT05590195) | Location not listed | Adjacent product trial | Status unconfirmed | 2024 (estimated)–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05590195) | [Permanent link](https://phage.directory/items/effect-of-preforpro-on-urinary-and-vaginal-health-9b8b901b4ca052098383316ceb6c8d96) |
| Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic (NCT03395743) | Location not listed | Expanded access | Unavailable | Not listed | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT03395743) | [Permanent link](https://phage.directory/items/individual-patient-expanded-access-for-ab-pa01-an-investigational-anti-pseudomonas-aerugin-a202d453c27d5cd295bee0489b879c81) |
| Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic (NCT03395769) | Location not listed | Expanded access | Unavailable | Not listed | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT03395769) | [Permanent link](https://phage.directory/items/individual-patient-expanded-access-for-ab-sa01-an-investigational-anti-staphylococcus-aure-c3eba79c4d5e5be8a0f5cd97d16b2ba7) |
| Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia (NCT04636554) | Location not listed | Expanded access | Unavailable | Not listed | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04636554) | [Permanent link](https://phage.directory/items/personalized-phage-treatment-in-covid-19-patients-with-bacterial-co-infections-microbials-ba78ae71afec5e2eb4e40dc70d29486f) |
| PHAGE Study: Bacteriophages as Novel Prebiotics (NCT03269617) | Location not listed | Adjacent product trial | Completed | 2016–2017 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT03269617) | [Permanent link](https://phage.directory/items/phage-study-bacteriophages-as-novel-prebiotics-f7ffd77d2993548ebddae9f9f4cf7c86) |
| Phage Therapy (NCT07382271) | Location not listed | Trial | Not yet recruiting | 2026 (estimated)–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07382271) | [Permanent link](https://phage.directory/items/evaluation-of-safety-and-efficacy-of-phage-therapy-for-drug-resistant-bacterial-infections-a108c5826c775356a8a5ba3a42409d43) |
| Phage Therapy for the Prevention and Treatment of Pressure Ulcers. (NCT04815798) | Location not listed | Trial | Status unconfirmed | 2022 (estimated)–2023 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04815798) | [Permanent link](https://phage.directory/items/phage-therapy-for-the-prevention-and-treatment-of-pressure-ulcers-4850300983cf5aa2834b3369a1f62294) |
| Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients (NCT04323475) | Location not listed | Trial | Status unconfirmed | 2022 (estimated)–2023 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04323475) | [Permanent link](https://phage.directory/items/phage-therapy-for-the-prevention-and-treatment-of-wound-infections-in-burned-patients-543b5034f745523a97419ed35bc8bc0f) |
| Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections (NCT07280598) | Location not listed | Trial | Not yet recruiting | 2025 (estimated)–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07280598) | [Permanent link](https://phage.directory/items/safety-of-combined-intravenous-antibiotic-and-bacteriophage-therapy-in-adults-with-cystic-ada2875fe80d5f059ca23c16d12c0650) |
| Amsterdam Medical Center — Amsterdam | Netherlands | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| UMC Utrecht personalized phage therapy program | Netherlands | Center | Case-by-case; Intake unconfirmed | — | 2026-10-04 | [1](https://research.umcutrecht.nl/news/first-experimental-therapy-at-umc-utrecht-with-personalized-bacteriophages/) [2](https://research.umcutrecht.nl/news/4-million-for-study-with-personalized-phage-therapy/) [3](https://www.umcutrecht.nl/nl/wetenschappelijk-onderzoek/chronisch-recidiverende-urineweginfecties) | [Permanent link](https://phage.directory/items/umc-utrecht-personalized-phage-therapy-program-287809c06ace5853a2180738c850b7d7) |
| University Medical Center Utrecht — Utrecht | Netherlands | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| TP-122_101A (2025-521533-85-00) | Netherlands; Portugal | Trial | Not yet recruiting | Not listed | 2026-10-03 | [1](https://euclinicaltrials.eu/ctis-public/view/2025-521533-85-00?lang=en) | [Permanent link](https://phage.directory/items/tp-122-101a-ea4dc8134d4a58589bbbc7e7599107f6) |
| University of Otago phage research | New Zealand | Research | Research/development | — | 2026-10-03 | [1](https://www.otago.ac.nz/microbiology-and-immunology/our-people/peter-fineran) [2](https://www.hrc.govt.nz/resources/research-repository/genomics-led-approach-bacteriophage-therapies-infectious-disease) | [Permanent link](https://phage.directory/items/university-of-otago-phage-research-181d96b25ed65ca89d8918b650f980d9) |
| Experimental Phage Therapy of Bacterial Infections (NCT00945087) | Poland | Trial | Status unconfirmed | Started 2005 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT00945087) | [Permanent link](https://phage.directory/items/experimental-phage-therapy-of-bacterial-infections-5cb579a4601a5036a48fce65555bf013) |
| Hirszfeld Institute Phage Therapy Unit | Poland | Center | Official referral/inquiry route | — | 2026-10-03 | [1](https://hirszfeld.pl/en/structure/iitd-pan-medical-center/phage-therapy-unit/) | [Permanent link](https://phage.directory/items/hirszfeld-institute-phage-therapy-unit-d806e48f3cbb55b0a3ae0eb4d7b57bc4) |
| Phage Therapy Unit at the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences — Wroclaw | Poland | Trial site | Status unconfirmed (trial) | Started 2005 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT00945087) | — |
| TechnoPhage | Portugal | Company | Provider-listed inquiry route | — | 2026-10-03 | [1](https://technophage.pt/expanded-access/) [2](https://technophage.pt/technophage-receives-regulatory-approval-to-initiate-phase-1-2a-tp-122-clinical-study-in-europe/) [3](https://clinicaltrials.gov/study/NCT05948592) [4](https://clinicaltrials.gov/study/NCT06370598) [5](https://euclinicaltrials.eu/ctis-public/view/2025-521533-85-00?lang=en) | [Permanent link](https://phage.directory/items/technophage-84d05f26d1885786a85f3da1500e1d78) |
| Budgetary Healthcare Institution of Arkhangelsk Region "Severodvinsk City Clinical Emergency Hospital # 2" — Severodvinsk, Arkhangelskaya oblast | Russia | Trial site | Historical trial site | 2020–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04325685) | — |
| NPO Microgen | Russia | Supplier | Provider-listed inquiry route | — | 2026-10-03 | [1](https://microgen.ru/products/) | [Permanent link](https://phage.directory/items/npo-microgen-c7476cab764d5ca7820f0f0e5cd53015) |
| PHARAOH (NCT06870409) | Russia | Trial | Recruiting | 2025–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06870409) | [Permanent link](https://phage.directory/items/bacteriophages-in-addition-to-antibiotics-for-the-treatment-of-patients-with-infective-end-167fa508207e531789516701a80db34b) |
| Research and Production Center Micromir | Russia | Supplier | Provider-listed inquiry route | — | 2026-10-03 | [1](https://micromircorp.ru/en) | [Permanent link](https://phage.directory/items/research-and-production-center-micromir-8527d66d500e5633bcee2bca31e422eb) |
| RUDN / V.V. Vinogradov Clinical Hospital PHARAOH | Russia | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06870409) | [Permanent link](https://phage.directory/items/rudn-v-v-vinogradov-clinical-hospital-pharaoh-5e94f35de23a5221a0e5ccf7fe4ba6d2) |
| SGDC-VAP (NCT04325685) | Russia | Trial | Completed | 2020–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04325685) | [Permanent link](https://phage.directory/items/the-effect-of-supraglottic-and-oropharyngeal-decontamination-on-the-incidence-of-ventilato-23e27e858238501da0cc7079596ceede) |
| University Clinical Hospital named after V.V.Vinogradov (branch) of the Peoples' Friendship University of Russia named after Patrice Lumumba — Moscow | Russia | Trial site | Recruiting (trial) | 2025–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06870409) | — |
| Singapore General Hospital | Singapore | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.sgh.com.sg/news/patient-care/century-old-therapy-used-to-treat-sgh-patient-with-antibiotic-re) | [Permanent link](https://phage.directory/items/singapore-general-hospital-af839d8ff33b5ce9acd1c37303e108ff) |
| JAFRAL | Slovenia | Supplier | Research/development | — | 2026-10-03 | [1](https://www.jafral.com/company) | [Permanent link](https://phage.directory/items/jafral-3cdb311567fb5105bb52c0a61a905f1b) |
| TASK / Phages4TB consortium | South Africa | Company | Research/development | — | 2026-10-03 | [1](https://cordis.europa.eu/project/id/101063247/reporting) [2](https://taskclinical.com/about-us/) | [Permanent link](https://phage.directory/items/task-phages4tb-consortium-cd38f574583e5cb39ca19a145e5c660a) |
| MicrobiotiX Co Ltd | South Korea | Company | Research/development | — | 2026-10-03 | [1](https://www.microbiotix.net/introduce) [2](https://www.microbiotix.net/media/?bmode=view&idx=173474265&q=YToxOntzOjEyOiJrZXl3b3JkX3R5cGUiO3M6MzoiYWxsIjt9&t=board) [3](https://clinicaltrials.gov/study/NCT07492771) | [Permanent link](https://phage.directory/items/microbiotix-co-ltd-c5835579838a548281ad5c028fc07288) |
| MP101-1001 (NCT07492771) | South Korea | Trial | Recruiting | 2026–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07492771) | [Permanent link](https://phage.directory/items/mp101-in-adults-with-acute-pseudomonas-aeruginosa-pneumonia-912bf10d155a573593cb4805d4cf642d) |
| Severance Hospital — MP101 pneumonia trial | South Korea | Center | Official referral/inquiry route | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07492771) | [Permanent link](https://phage.directory/items/severance-hospital-mp101-pneumonia-trial-d38939af5bb85063ad924cda874068b1) |
| Severance Hospital — Seoul, Seodaemun-gu | South Korea | Trial site | Recruiting (trial) | 2026–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07492771) | — |
| Evolving Therapeutics | Spain | Supplier | Intake unconfirmed | — | 2026-10-04 | [1](https://i2sysbio.es/communication/1338/) [2](https://www.evolvingtherapeutics.es/) [3](https://evolvingtherapeutics.es/contact/) | [Permanent link](https://phage.directory/items/evolving-therapeutics-3c04c4ffa44a5d9782ed825869c3d169) |
| Hospital Clinico Universitario Virgen de la Arrixaca — El Palmar, Murcia | Spain | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| I2SysBio / University of Valencia-CSIC phage group | Spain | Supplier | Intake unconfirmed | — | 2026-10-04 | [1](https://i2sysbio.es/communication/1338/) [2](https://www.uv.es/uvweb/uv-news/en/news/university-csic-obtain-first-clinical-results-viruses-destroy-multi-drug-resistant-bacteria-1285973304159/Novetat.html?id=1286389304279&idA=&plantilla=UV_Noticies%2FPage%2FTPGDetaillNews) | [Permanent link](https://phage.directory/items/i2sysbio-university-of-valencia-csic-phage-group-a521676fcdfc5562a6b95e55805a1e6d) |
| INIBIC / CHUAC MicroTM phage research group | Spain | Research | Research/development | — | 2026-10-04 | [1](https://www.inibic.es/portfolio-items/grupo-de-microbiologia-traslacional-y-multidisciplinar-microtm/amp/) | [Permanent link](https://phage.directory/items/inibic-chuac-microtm-phage-research-group-a1d4b92d7d17577aa7ae89ceca02d93c) |
| La Fe University Hospital phage therapy activity | Spain | Center | Case-by-case; Intake unconfirmed | — | 2026-10-04 | [1](https://www.uv.es/uvweb/uv-news/en/news/university-csic-obtain-first-clinical-results-viruses-destroy-multi-drug-resistant-bacteria-1285973304159/Novetat.html?id=1286389304279&idA=&plantilla=UV_Noticies%2FPage%2FTPGDetaillNews) | [Permanent link](https://phage.directory/items/la-fe-university-hospital-phage-therapy-activity-17a828b9b44b5d148c9c71d73420ccb6) |
| Vall d'Hebron Barcelona Hospital Campus — Barcelona | Spain | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| Virgen del Rocío Hospital phage therapy activity | Spain | Center | Case-by-case; Intake unconfirmed | — | 2026-10-04 | [1](https://www.uv.es/uvweb/uv-news/en/news/university-csic-obtain-first-clinical-results-viruses-destroy-multi-drug-resistant-bacteria-1285973304159/Novetat.html?id=1286389304279&idA=&plantilla=UV_Noticies%2FPage%2FTPGDetaillNews) | [Permanent link](https://phage.directory/items/virgen-del-rocio-hospital-phage-therapy-activity-68489458848357119e2b30fb6e7f10eb) |
| GLORIA (NCT06605651) | Spain; France; Netherlands | Trial | Not yet recruiting | 2026 (estimated)–2029 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06605651) [2](https://euclinicaltrials.eu/ctis-public/view/2024-516555-40-00?lang=en) | [Permanent link](https://phage.directory/items/proof-of-concept-study-to-assess-safety-and-efficacy-of-phage-therapy-in-hip-or-knee-prost-c33b13c18d7e5a0f93769435d0f086b6) |
| Karolinska University Hospital / Karolinska Institutet phage program | Sweden | Research | Intake unconfirmed | — | 2026-10-03 | [1](https://www.karolinska.se/om-oss/centrala-nyheter/2024/10/innovationsdagen-2024/) | [Permanent link](https://phage.directory/items/karolinska-university-hospital-karolinska-institutet-phage-program-4be63316b5d85141b95170fc440b32ab) |
| Balgrist Phage Therapy and Research / REPhRAME | Switzerland | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.balgrist.ch/ueber-uns/medien/mit-viren-gegen-bakterien-eu-foerdert-phagentherapie-mit-15-millionen-euro-1011/) | [Permanent link](https://phage.directory/items/balgrist-phage-therapy-and-research-rephrame-5465b241a155534ebb0cf65493f59120) |
| Centre Hospitalier Universitaire Vaudois — Lausanne | Switzerland | Trial site | Historical trial site | 2015–2017 | 2026-10-04 | [1](https://clinicaltrials.gov/study/NCT02116010) | — |
| CHUV bacteriophage and phagotherapy laboratory | Switzerland | Research | Research/development | — | 2026-10-03 | [1](https://www.chuv.ch/fr/crisp/therapies-innovantes-biologiques-et-cellulaires/laboratoire-des-bacteriophages-et-de-phagotherapie) [2](https://www.chuv.ch/fr/evenements/evenement/news_evt_783/forum-phagotherapie-debat-grand-public-avec-les-acteurs-concernes) | [Permanent link](https://phage.directory/items/chuv-bacteriophage-and-phagotherapy-laboratory-75d54ad0674d5987ba4561d1ce964aa2) |
| Geneva University Hospitals (HUG) clinical phage experience | Switzerland | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://panorama.hug.ch/2023/un-patient-sauve-de-lantibioresistance-grace-aux-bacteriophages/) [2](https://www.hug.ch/sites/interhug/files/presse/2023.06.27-cp_bacteriophages_1.pdf) | [Permanent link](https://phage.directory/items/geneva-university-hospitals-hug-clinical-phage-experience-f961d021685a53c7b8a101d49fde4776) |
| Micreos Pharmaceuticals AG / Micreos Group | Switzerland; Netherlands | Company | Research/development | — | 2026-10-03 | [1](https://micreos.com/) [2](https://micreosgroup.com/) | [Permanent link](https://phage.directory/items/micreos-pharmaceuticals-ag-micreos-group-1f922683c29b5a59bd3d1183ba0db345) |
| Mahidol University / Siriraj phage research | Thailand | Research | Research/development | — | 2026-10-03 | [1](https://www.si.mahidol.ac.th/Th/department/immunology/news_detail.asp?id=482&m=1&y=2566) [2](https://amric.mahidol.ac.th/research.html) | [Permanent link](https://phage.directory/items/mahidol-university-siriraj-phage-research-b03d632e53515354b4f6d4dda9c9d564) |
| PrimaVac / PRIMAFAG | Ukraine | Supplier | Provider-listed inquiry route | — | 2026-10-03 | [1](https://primavac.com.ua/) | [Permanent link](https://phage.directory/items/primavac-primafag-2de27936263a5e2eb93e40726b592cf5) |
| Biocontrol Ltd | United Kingdom | Company | Acquired by AmpliPhi in 2011 | — | 2026-10-03 | [1](https://www.sec.gov/Archives/edgar/data/921114/000155837020002943/armp-20191231x10k.htm) | [Permanent link](https://phage.directory/items/biocontrol-ltd-17e2b9037eda56bba5167451c9bb6dbb) |
| Great Ormond Street Hospital (GOSH) | United Kingdom | Supplier | Intake unconfirmed | — | 2026-10-04 | [1](https://www.gosh.nhs.uk/wards-and-departments/departments/laboratory-medicine/laboratory-database/phage-reconstitution/) [2](https://www.gosh.nhs.uk/news/first-use-pioneering-phage-virus-therapy-treat-patient-cystic-fibrosis/) | [Permanent link](https://phage.directory/items/great-ormond-street-hospital-gosh-e973dbc343ad5509bb28259561a13490) |
| NexaBiome (formerly Fixed Phage) | United Kingdom | Company | Research/development | — | 2026-10-03 | [1](https://nexabiome.com/) [2](https://gk.news/fixedphage/press-release/) | [Permanent link](https://phage.directory/items/nexabiome-formerly-fixed-phage-2e5c19e75b7455f8b9171bef6cfb3ee2) |
| NHS Tayside / Ninewells phage therapy program | United Kingdom | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://shtg.scot/our-advice/bacteriophage-therapy-for-patients-with-difficult-to-treat-bacterial-infections/) [2](https://discovery.dundee.ac.uk/ws/files/149452593/antibiotics-14-00114.pdf) | [Permanent link](https://phage.directory/items/nhs-tayside-ninewells-phage-therapy-program-7fe98a0443ba5086bcadbd4a340043d9) |
| PDFI (NCT04289948) | United Kingdom | Trial | Withdrawn | 2019 (estimated)–2022 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04289948) | [Permanent link](https://phage.directory/items/assessing-the-efficacy-of-anti-staphylococcal-phages-in-the-management-of-infected-foot-ul-9aad11f9a086580aafa440554d0c7eef) |
| Phage UK | United Kingdom | Facilitator | Status unconfirmed | — | 2026-10-03 | [1](https://phageuk.org/general-enquiries) [2](https://committees.parliament.uk/writtenevidence/116523/pdf/) | [Permanent link](https://phage.directory/items/phage-uk-5df0a8e3dfee5fbbb92a72c3bbf1e56f) |
| SASPiPhi Limited / STEPS-CF | United Kingdom | Company | Research/development | — | 2026-10-03 | [1](https://www.isrctn.com/ISRCTN57413769) | [Permanent link](https://phage.directory/items/saspiphi-limited-steps-cf-787e468774775eaf85b1ff4f84526e6a) |
| STEPS-CF / SASPject PT3.9 (ISRCTN57413769) | United Kingdom | Trial | Not yet recruiting | 2027 (estimated)–2029 (estimated) | 2026-10-03 | [1](https://www.isrctn.com/ISRCTN57413769) | [Permanent link](https://phage.directory/items/steps-cf-saspject-pt3-9-555bc0b9fa5d504db2ec9ed33f70ca96) |
| UK Phage Therapy | United Kingdom | Facilitator | Status unconfirmed | — | 2026-10-03 | [1](https://www.ukphagetherapy.org/) [2](https://committees.parliament.uk/writtenevidence/116672/pdf/) | [Permanent link](https://phage.directory/items/uk-phage-therapy-44c1282daf1f53579bdb951b8eb0c1ae) |
| University Hospitals Derby and Burton NHS Foundation Trust — Derby, Derbyshire | United Kingdom | Trial site | Historical trial site | 2019 (estimated)–2022 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04289948) | — |
| University of Exeter phage research / phage library | United Kingdom | Research | Research/development | — | 2026-10-03 | [1](https://www.exeter.ac.uk/research/amr/reducing-antibiotic-use/) | [Permanent link](https://phage.directory/items/university-of-exeter-phage-research-phage-library-334f48b3b3c457919acf3f9750076788) |
| A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa (NCT05453578) | United States | Trial | Completed | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | [Permanent link](https://phage.directory/items/a-phase-1b-2-trial-of-the-safety-and-microbiological-activity-of-bacteriophage-therapy-in-0b6d06a30e645c8d94f2fa3c49615df6) |
| A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects (NCT05277350) | United States | Trial | Completed | 2022–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05277350) | [Permanent link](https://phage.directory/items/a-study-investigating-the-safety-recovery-and-pharmacodynamics-of-multiple-oral-administra-6c867a88f4d45a81b8f6151116e5776f) |
| A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults (NCT04737876) | United States | Trial | Completed | 2020–2020 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04737876) | [Permanent link](https://phage.directory/items/a-study-to-evaluate-the-safety-tolerability-and-fecal-pharmacokinetics-of-bx002-a-in-healt-aa0b4be557ab5ebfbeccfeb7d8c3745f) |
| ACTIVE2 (NCT05269134) | United States | Trial | Withdrawn | 2023–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269134) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-in-patients-with-prosthetic-joint-infections-pji-17097995b1105f178f95adf35085ba26) |
| AdMed Research — Miami, Florida | United States | Trial site | Historical trial site | 2020–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04287478) | — |
| AmpliPhi Biosciences | United States | Company | Renamed Armata in 2019 | — | 2026-10-03 | [1](https://www.sec.gov/Archives/edgar/data/921114/000155837020002943/armp-20191231x10k.htm) | [Permanent link](https://phage.directory/items/ampliphi-biosciences-05480b7ee3b1590098700fe4d78b762f) |
| AMPM Research Clinic — Miami Gardens, Florida | United States | Trial site | Historical trial site | 2019–2020; 2020–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04191148) [2](https://clinicaltrials.gov/study/NCT04287478) | — |
| Armata Pharmaceuticals | United States | Company | Research/development | — | 2026-10-03 | [1](https://www.armatapharma.com/pipeline/ap-sa02/) [2](https://www.armatapharma.com/pipeline/pipeline-overview/) [3](https://www.armatapharma.com/contact-us/) [4](https://clinicaltrials.gov/study/NCT05184764) [5](https://clinicaltrials.gov/study/NCT05616221) [6](https://clinicaltrials.gov/study/NCT03395743) [7](https://clinicaltrials.gov/study/NCT03395769) | [Permanent link](https://phage.directory/items/armata-pharmaceuticals-b51d2132a0c352da891b974e30dddd09) |
| Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults (NCT02757755) | United States | Trial | Completed | 2016–2016 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT02757755) | [Permanent link](https://phage.directory/items/ascending-dose-study-of-the-safety-of-ab-sa01-when-topically-applied-to-intact-skin-of-hea-196b826dfc885300a38fba74145153a1) |
| Avanza Medical Center — Pensacola, Florida | United States | Trial site | Conflicting status (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06998043) | — |
| Bacteriophage Therapy in Patients With Prosthetic Joint Infections (NCT04787250) | United States | Trial | Withdrawn | 2022 (estimated)–2024 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04787250) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-in-patients-with-prosthetic-joint-infections-727277c967475b7d95a26d7457fef85f) |
| Bacteriophage Therapy in Patients With Urinary Tract Infections (NCT04287478) | United States | Trial | Terminated | 2020–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04287478) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-in-patients-with-urinary-tract-infections-4ba9d50c45235ddcbce7e435e9f17d25) |
| Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection (NCT07275905) | United States | Trial | Recruiting | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07275905) | [Permanent link](https://phage.directory/items/bacteriophages-for-adults-with-cystic-fibrosis-and-chronic-achromobacter-lung-infection-601fc44da2d95a09bea0ff1e9f500f54) |
| Banner University Medical Center — Tucson, Arizona | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Baylor College of Medicine — Houston, Texas | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| Baylor College of Medicine TAILOR | United States | Supplier | Case-by-case; Intake unconfirmed | — | 2026-10-03 | [1](https://www.bcm.edu/research/research-centers/tailor) | [Permanent link](https://phage.directory/items/baylor-college-of-medicine-tailor-481ea596ee5f516791a74d3f40b44248) |
| Baylor College of Medicine, Texas Children Clinic — Houston, Texas | United States | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| Bio X Cell Research LLC — San Antonio, Texas | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Biomarkers of Phage Treatment Response in NTM and Other Infections (NCT07076238) | United States | Observational study | Recruiting | 2025–2032 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07076238) | [Permanent link](https://phage.directory/items/biomarkers-of-phage-treatment-response-in-ntm-and-other-infections-2f17bfe1938f518ea844f2be4c31fc12) |
| Boston Children's Hospital — Boston, Massachusetts | United States | Trial site | Historical trial site | 2020–2022; 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) [2](https://clinicaltrials.gov/study/NCT05010577) | — |
| Boston Childrens Hospital — Boston, Massachusetts | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| Brigham & Women's Hospital — Boston, Massachusetts | United States | Trial site | Historical trial site | 2023–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269134) | — |
| C3J Therapeutics | United States | Company | Merged into Armata 2019 | — | 2026-10-03 | [1](https://www.sec.gov/Archives/edgar/data/921114/000155837020002943/armp-20191231x10k.htm) | [Permanent link](https://phage.directory/items/c3j-therapeutics-19a9292d1422551dbae94f41fb68d691) |
| Case Western Reserve University — Cleveland, Ohio | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| Central Florida Pulmonary Group — Orlando, Florida | United States | Trial site | Conflicting status (trial) | 2022–2024; 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) [2](https://clinicaltrials.gov/study/NCT06998043) | — |
| Children's Hospital Los Angeles — Los Angeles, California | United States | Trial site | Historical trial site | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | — |
| Children's Hospital of Los Angeles — Los Angeles, California | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| Children's National Medical Center — Washington D.C., District of Columbia | United States | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| Childrens Hospital Colorado — Denver, Colorado | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| Cincinnati Children's Hospital — Cincinnati, Ohio | United States | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| City of Hope — Duarte, California | United States | Trial site | Recruiting (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06938867) | — |
| Clemente Clinical Research — Los Angeles, California | United States | Trial site | Historical trial site | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) | — |
| Clinical Trials Center, WRAIR — Silver Spring, Maryland | United States | Trial site | Historical trial site | 2016–2016 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT02757755) | — |
| Colorado State University — Fort Collins, Colorado | United States | Trial site | Recruiting (trial) | 2018–2020; 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04511221) [2](https://clinicaltrials.gov/study/NCT07816809) | — |
| Columbia University — New York, New York | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| CurAlta Foot and Ankle — Westwood, New Jersey | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| CYstic Fibrosis bacterioPHage Study at Yale (CYPHY) (NCT04684641) | United States | Trial | Completed | 2021–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04684641) | [Permanent link](https://phage.directory/items/cystic-fibrosis-bacteriophage-study-at-yale-cyphy-33d5ef5219c757598dd5d49ce8dce195) |
| DANCE (NCT05177107) | United States | Trial | Terminated | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-in-patients-with-diabetic-foot-osteomyelitis-3ef0119d874b58b7b9288d6b0bb92eb5) |
| Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| DHR Health Institute for Research and Development — Edinburg, Texas | United States | Trial site | Historical trial site | 2020–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04287478) | — |
| doTERRA International — Pleasant Grove, Utah | United States | Trial site | Historical trial site | 2025–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06931977) | — |
| Duke University Medical Center — Durham, North Carolina | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| ELIMINATE (NCT05488340) | United States | Trial | Recruiting | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | [Permanent link](https://phage.directory/items/a-study-of-lbp-ec01-in-the-treatment-of-acute-uncomplicated-uti-caused-by-drug-resistant-e-092ecdb4ac515d96a5fdca5d1f9d4cc7) |
| Emory University - Adult Cystic Fibrosis Program — Atlanta, Georgia | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| Emory University Hospital Midtown — Atlanta, Georgia | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Food and Nutrition Clinical Research Lab(FNCRL), Colorado State University — Fort Collins, Colorado | United States | Trial site | Historical trial site | 2021–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05750433) | — |
| Foot & Ankle Center of Illinois — Springfield, Illinois | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Foot and Ankle Specialists of the Mid-Atlantic — Salem, Virginia | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Fred Hutchinson Cancer Center — Seattle, Washington | United States | Trial site | Recruiting (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06938867) | — |
| Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Futuro Clinical Trials, LLC — McAllen, Texas | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Georgetown University Hospital / Pulmonary Critical Care and Sleep Medicine — Washington D.C., District of Columbia | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Gladstone Center for PhAIge Therapy | United States | Research | Research/development | — | 2026-10-03 | [1](https://gladstone.org/science/centers/center-for-phaige-therapy/) | [Permanent link](https://phage.directory/items/gladstone-center-for-phaige-therapy-db60b288ea00536298ed2c90c147e53e) |
| Harbor Hospital / UCLA — Torrance, California | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Harper University Hospital — Detroit, Michigan | United States | Trial site | Historical trial site | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | — |
| Hartford Health Care Bone & Joint Insitute — Hartford, Connecticut | United States | Trial site | Historical trial site | 2023–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269134) | — |
| Henry Ford Health — Detroit, Michigan | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Henry Ford Health System — Detroit, Michigan | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Henry Ford Hospital — Detroit, Michigan | United States | Trial site | Historical trial site | 2020–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04287478) | — |
| Holy Cross Health — Fort Lauderdale, Florida | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Holy Name Medical Center — Teaneck, New Jersey | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Icahn School of Medicine at Mount Sinai — New York, New York | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Icahn School of Medicine at Mount Sinai Hospital — New York, New York | United States | Trial site | Conflicting status (trial) | 2019–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT03808103) | — |
| Infectious Disease Consultants od the Treasure Coast — Sebastian, Florida | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Innovation Medical Research Center — Palmetto Bay, Florida | United States | Trial site | Historical trial site | 2019–2020 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04191148) | — |
| Innovation Medical Research Center, Inc — Palmetto Bay, Florida | United States | Trial site | Historical trial site | 2020–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04287478) | — |
| Intralytix | United States | Supplier | Official referral/inquiry route | — | 2026-10-03 | [1](https://www.intralytix.com/expanded-access) [2](https://www.intralytix.com/clinical-trials) [3](https://clinicaltrials.gov/study/NCT03808103) [4](https://clinicaltrials.gov/study/NCT05182749) [5](https://clinicaltrials.gov/study/NCT05715619) | [Permanent link](https://phage.directory/items/intralytix-a5131fe71a835d2fbf02e4ac488b09bc) |
| James J. Peters VA Medical Center — The Bronx, New York | United States | Trial site | Historical trial site | 2020–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04287478) | — |
| Joe DiMaggio Children's Health — Hollywood, Florida | United States | Trial site | Conflicting status (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06998043) | — |
| Joe DiMaggio Children's Hospital — Hollywood, Florida | United States | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| John Hopkins University — Baltimore, Maryland | United States | Trial site | Mixed trial statuses | 2024–2028 (estimated); 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) [2](https://clinicaltrials.gov/study/NCT06938867) | — |
| Johns Hopkins — EcoActive Crohn's research site | United States | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.intralytix.com/clinical-trial/5) [2](https://clinicaltrials.gov/study/NCT03808103) | [Permanent link](https://phage.directory/items/johns-hopkins-ecoactive-crohn-s-research-site-803bc17c77d75c408fcf6b0196ee8d28) |
| Johns Hopkins Green Spring Station — Lutherville, Maryland | United States | Trial site | Conflicting status (trial) | 2019–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT03808103) | — |
| Johns Hopkins University — Baltimore, Maryland | United States | Trial site | Historical trial site | 2020–2022; 2022–2025; 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) [2](https://clinicaltrials.gov/study/NCT05184764) [3](https://clinicaltrials.gov/study/NCT05453578) | — |
| Johns Hopkins University School of Medicine — Baltimore, Maryland | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Locus Biosciences | United States | Company | Official referral/inquiry route | — | 2026-10-03 | [1](https://www.locus-bio.com/pipeline/) [2](https://clinicaltrials.gov/study/NCT05488340) | [Permanent link](https://phage.directory/items/locus-biosciences-27fabc4274d156d681d07d8ec0e1aace) |
| Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center — Torrance, California | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Massachusetts General Hospital — Boston, Massachusetts | United States | Trial site | Historical trial site | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | — |
| Mayo Clinic — Rochester, Minnesota | United States | Trial site | Historical trial site | 2022 (estimated)–2024 (estimated); 2023–2027 (estimated); 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04787250) [2](https://clinicaltrials.gov/study/NCT05269134) [3](https://clinicaltrials.gov/study/NCT05616221) | — |
| Mayo Clinic Phage Program Biobank (NCT05314426) | United States | Observational study | Invitation only | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05314426) | [Permanent link](https://phage.directory/items/mayo-clinic-phage-program-biobank-e4fc08cbad11504897bf38fee937bbf5) |
| Mayo Clinic Phage Therapy Program | United States | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.mayoclinic.org/biographies/suh-gina-a-m-d/bio-20462452) [2](https://www.mayo.edu/research/clinical-trials/cls-20531162) [3](https://newsnetwork.mayoclinic.org/discussion/in-a-first-mayo-clinic-treats-cardiology-patient-with-phage-therapy/) [4](https://clinicaltrials.gov/study/NCT05314426) [5](https://clinicaltrials.gov/study/NCT04787250) | [Permanent link](https://phage.directory/items/mayo-clinic-phage-therapy-program-ab1c2c01adb55b17b9c2d1b87d99dcea) |
| Mayo Clinic Rochester — Rochester, Minnesota | United States | Trial site | Invitation only (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05314426) | — |
| Mayo Clinic/Pulmonary, Critical Care, and Sleep Medicine — Jacksonville, Florida | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Medical Facility — Cincinnati, Ohio | United States | Trial site | Historical trial site | 2020–2020 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04737876) | — |
| Medical University of South Carolina — Charleston, South Carolina | United States | Trial site | Historical trial site | 2020–2022; 2022–2024; 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) [2](https://clinicaltrials.gov/study/NCT05010577) [3](https://clinicaltrials.gov/study/NCT05616221) | — |
| Medpace Clinical Pharmacology — Cincinnati, Ohio | United States | Trial site | Historical trial site | 2022–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05277350) | — |
| Methodist Hospital Research Institute - Houston — Houston, Texas | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Michael E. DeBakey VA Medical Center — Houston, Texas | United States | Trial site | Recruiting (trial) | 2025–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06559618) | — |
| Michael E. DeBakey VA Medical Center — SCI bacteriuria trial | United States | Center | Official referral/inquiry route | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06559618) | [Permanent link](https://phage.directory/items/michael-e-debakey-va-medical-center-sci-bacteriuria-trial-4eaf6e7377885c1f898666c41ccb506a) |
| Michigan Medicine — Ann Arbor, Michigan | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| Montefiore Medical Center — The Bronx, New York | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Mount Sinai — EcoActive Crohn's research site | United States | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.intralytix.com/clinical-trial/5) [2](https://www.mountsinai.org/clinical-trials/safety-efficacy-of-ecoactive-on-intestinal-adherent-invasive-e-coli-in-patients-with-inactive-crohns-disease) [3](https://clinicaltrials.gov/study/NCT03808103) | [Permanent link](https://phage.directory/items/mount-sinai-ecoactive-crohn-s-research-site-fc10d87895c85559ad97e6e0ab6fe1dd) |
| National Jewish Health — Denver, Colorado | United States | Trial site | Mixed trial statuses | 2024–2028 (estimated); 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) [2](https://clinicaltrials.gov/study/NCT06998043) | — |
| National Jewish Health / POSTSTAMP | United States | Center | Intake unconfirmed | — | 2026-10-04 | [1](https://clinicaltrials.gov/study/NCT06262282) [2](https://www.nationaljewish.org/about-us/news/press-releases/2022-news/researchers-use-virus-to-fight-bacterial-infection%2C-clearing-way-for-life-saving-lung-transplant) | [Permanent link](https://phage.directory/items/national-jewish-health-poststamp-6a8459e6d74c5ba29b09362c64bdbc16) |
| Nationwide Children's Hospital — Columbus, Ohio | United States | Trial site | Invitation only (trial) | 2020–2022; 2022–2024; 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) [2](https://clinicaltrials.gov/study/NCT05010577) [3](https://clinicaltrials.gov/study/NCT06262282) | — |
| Natural Product System and Lifestyle Modification (NCT06931977) | United States | Adjacent product trial | Completed | 2025–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06931977) | [Permanent link](https://phage.directory/items/natural-product-system-and-lifestyle-modification-78814b62e90e55a58da36cb9468ba40d) |
| New England Baptist Hospital — Boston, Massachusetts | United States | Trial site | Historical trial site | 2023–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269134) | — |
| New York Medical College — Hawthorne, New York | United States | Trial site | Conflicting status (trial) | 2023–2024; 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) [2](https://clinicaltrials.gov/study/NCT06998043) | — |
| New York Medical College — Valhalla, New York | United States | Trial site | Historical trial site | 2020–2022; 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) [2](https://clinicaltrials.gov/study/NCT05010577) | — |
| NorthBay Healthcare — Fairfield, California | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Northwell Health — New Hyde Park, New York | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| Northwell Health — New York, New York | United States | Trial site | Conflicting status (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06998043) | — |
| Northwestern University — Chicago, Illinois | United States | Trial site | Invitation only (trial) | 2020–2022; 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) [2](https://clinicaltrials.gov/study/NCT06262282) | — |
| NYU Langone Health — New York, New York | United States | Trial site | Recruiting (trial) | 2025–2032 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07076238) | — |
| NYU Langone NTM/bronchiectasis phage program | United States | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://physicianfocus.nyulangone.org/advancing-phage-therapy-for-nontuberculosis-mycobacteria-infection-and-bronchiectasis/) [2](https://clinicaltrials.gov/study/NCT07076238) | [Permanent link](https://phage.directory/items/nyu-langone-ntm-bronchiectasis-phage-program-b343e3c105ec519ba7032a0c512648d1) |
| Oregon Health & Science University — Portland, Oregon | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Penn State Health Milton S. Hershey Medical Center — Hershey, Pennsylvania | United States | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| Phage (NCT06559618) | United States | Trial | Recruiting | 2025–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06559618) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-in-spinal-cord-injury-patients-with-bacteriuria-045f44bd2ea7553997115c801f8a3357) |
| Phage 3Determination of Phage/Probiotic Synergistic Effects on Gastrointestinal Health (NCT05750433) | United States | Adjacent product trial | Completed | 2021–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05750433) | [Permanent link](https://phage.directory/items/phage-3determination-of-phage-probiotic-synergistic-effects-on-gastrointestinal-health-324ca77ecae35e9a8689c062af9c720a) |
| Phage International Inc. | United States | Company | Ceased operations 2023 | — | 2026-10-03 | [1](https://www.phagetherapycenter.com/pii/PatientServlet?command=responsive_ourhistory) | [Permanent link](https://phage.directory/items/phage-international-inc-47a2aee6e6b05760be7fd43356c20955) |
| Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients (NCT06409819) | United States | Trial | Recruiting | 2025–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06409819) | [Permanent link](https://phage.directory/items/phage-therapy-for-recurrent-utis-in-kidney-transplant-recipients-8ac608a3710b57069555aee5915369fe) |
| Phage-CLEAR (NCT07816809) | United States | Adjacent product trial | Recruiting | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07816809) | [Permanent link](https://phage.directory/items/phage-based-control-and-limitation-of-pathobionts-for-microbiome-equilibrium-and-resilienc-5583c646df12557da18ffc591a3146d0) |
| PHAGE2 (NCT04511221) | United States | Adjacent product trial | Completed | 2018–2020 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04511221) | [Permanent link](https://phage.directory/items/bacteriophage-for-gastrointestinal-health-2-study-895becacc4c4531cad7984533aaddf8c) |
| PhagePro | United States | Company | Research/development | — | 2026-10-03 | [1](https://www.phageproinc.com/who-we-are) | [Permanent link](https://phage.directory/items/phagepro-147643890e9359a59b3c479a5a5714b4) |
| Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant (NCT06938867) | United States | Trial | Recruiting | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06938867) [2](https://www.sniprbiome.com/) | [Permanent link](https://phage.directory/items/phase-1b-2a-randomized-double-blind-study-to-investigate-safety-tolerability-pk-pd-prelimi-64c957f6dbd95d459f29072a55037ff8) |
| Phiogen | United States | Company | Research/development | — | 2026-10-03 | [1](https://www.phiogenpharma.com/) | [Permanent link](https://phage.directory/items/phiogen-4d5f339c599b5bc7ac979c5915708b7a) |
| PhoenixAH (NCT06750588) | United States | Trial | Not yet recruiting | 2025 (estimated)–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06750588) | [Permanent link](https://phage.directory/items/safety-and-tolerability-of-ntr-101-in-patients-with-acute-alcohol-associated-hepatitis-d039305f6e9d5d10a08773787967aa9d) |
| Pinnacle Research Group — Anniston, Alabama | United States | Trial site | Historical trial site | 2019–2020 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04191148) | — |
| Pittsburgh Phage Program (P3), University of Pittsburgh/UPMC | United States | Center | Case-by-case; Official referral/inquiry route | — | 2026-10-03 | [1](https://dom.pitt.edu/id/research/phage/) [2](https://clinicaltrials.gov/study/NCT07275905) | [Permanent link](https://phage.directory/items/pittsburgh-phage-program-p3-university-of-pittsburgh-upmc-42d651272043584791a4e3010dd22c37) |
| Podiatry 1st / Gateway Clinical Trials — O'Fallon, Illinois | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| POSTSTAMP (NCT06262282) | United States | Observational study | Invitation only | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | [Permanent link](https://phage.directory/items/mycobacteriophage-treatment-of-non-tuberculosis-mycobacteria-2c3eba0c61d35bdabae61bfbc22de974) |
| Providence Alaska Medical Center — Anchorage, Alaska | United States | Trial site | Conflicting status (trial) | 2022–2024; 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) [2](https://clinicaltrials.gov/study/NCT06998043) | — |
| Ralph H. Johnson VA Medical Center — Charleston, South Carolina | United States | Trial site | Historical trial site | 2019–2020 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04191148) | — |
| Regional One Healthcare — Memphis, Tennessee | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Research Site 102 — Doral, Florida | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 103 — Miami, Florida | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 118 — Winston-Salem, North Carolina | United States | Trial site | Completed (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 120 — Boston, Massachusetts | United States | Trial site | Completed (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 123 — Los Angeles, California | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 125 — Montebello, California | United States | Trial site | Completed (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 126 — Tustin, California | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 131 — Lancaster, California | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 137 — San Diego, California | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 138 — Fresno, California | United States | Trial site | Completed (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 140 — Jensen Beach, Florida | United States | Trial site | Completed (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 145 — Raleigh, North Carolina | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 149 — Miami, Florida | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 151 — Hialeah, Florida | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 152 — Murrieta, California | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 153 — Ocala, Florida | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Research Site 154 — St Louis, Missouri | United States | Trial site | Recruiting (trial) | 2022–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05488340) | — |
| Rhode Island Hospital — Providence, Rhode Island | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Rocky Mountain Regional VA Medical Center — Aurora, Colorado | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Rocky Mountain VA — Aurora, Colorado | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Rutgers Robert Wood Johnson Medical School — New Brunswick, New Jersey | United States | Trial site | Historical trial site | 2020–2022; 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) [2](https://clinicaltrials.gov/study/NCT05616221) | — |
| Rutgers, Robert Wood Johnson Medical School — New Brunswick, New Jersey | United States | Trial site | Conflicting status (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06998043) | — |
| Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease (NCT03808103) | United States | Trial | Conflicting status | 2019–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT03808103) [2](https://www.intralytix.com/clinical-trial/5) | [Permanent link](https://phage.directory/items/safety-and-efficacy-of-ecoactive-on-intestinal-adherent-invasive-e-coli-in-patients-with-i-c2756f0a31b05efa8baa48c7cc23d926) |
| Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects (NCT05715619) | United States | Trial | Suspended | 2023–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05715619) | [Permanent link](https://phage.directory/items/safety-and-efficacy-of-oral-administration-of-the-phage-cocktail-vrelysintm-in-healthy-and-0ea3354d342a597b92f801058674ee00) |
| Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis (NCT05182749) | United States | Trial | Active, not recruiting | 2023–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05182749) | [Permanent link](https://phage.directory/items/safety-and-efficacy-of-the-bacteriophage-preparation-shigactivetm-in-a-human-experimental-661a9fcf56aa5e9db6ed536d857d3a11) |
| Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli (NCT04191148) | United States | Trial | Completed | 2019–2020 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04191148) | [Permanent link](https://phage.directory/items/safety-tolerability-and-pk-of-lbp-ec01-in-patients-with-lower-urinary-tract-colonization-c-834d7dc5077c573fa1b915c72e5421e8) |
| Salem VA — Salem, Virginia | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Seattle Children's Hospital — Seattle, Washington | United States | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| Sinai Hospital of Baltimore — Baltimore, Maryland | United States | Trial site | Historical trial site | 2023–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269134) | — |
| Snake River Research — Idaho Falls, Idaho | United States | Trial site | Historical trial site | 2023–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269134) | — |
| Southern Arizona VA Health Care System — Tuscon, Arizona | United States | Trial site | Historical trial site | 2021–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05177107) | — |
| Southern California Institute for Respiratory Diseases Cedars-Sinai West Tower — Los Angeles, California | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Southern California Research Center, inc — Coronado, California | United States | Trial site | Not yet recruiting (trial) | 2025 (estimated)–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06750588) | — |
| Southweast Regional Wound Care Center — Lubbock, Texas | United States | Trial site | Historical trial site | 2006–2008 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT00663091) | — |
| Southwest General Healthcare Center — Fort Myers, Florida | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Southwestern Medical Center at Dallas — Dallas, Texas | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| St. Luke's Cystic Fibrosis Center of Idaho — Boise, Idaho | United States | Trial site | Historical trial site | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | — |
| St. Lukes Hospital — Boise, Idaho | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Stanford Center for Phage Pharmaceuticals | United States | Research | Research/development | — | 2026-10-03 | [1](https://med.stanford.edu/news/all-news/2026/06/bollyky-niaid-grant.html) | [Permanent link](https://phage.directory/items/stanford-center-for-phage-pharmaceuticals-2a04ef586fb5529c8ba02512c71d7537) |
| Stanford University — Palo Alto, California | United States | Trial site | Conflicting status (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06998043) | — |
| Stanford University — Stanford, California | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| SWARM-Pa (NCT04596319) | United States | Trial | Completed | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | [Permanent link](https://phage.directory/items/ph-1-2-study-evaluating-safety-and-tolerability-of-inhaled-ap-pa02-in-subjects-with-chroni-0d3910c4ec4b5f39bfd57f3bbc97f7ab) |
| Tabula Bioscience | United States | Company | Official referral/inquiry route | — | 2026-10-03 | [1](https://www.tabulabio.com/expanded-access) [2](https://www.tabulabio.com/) | [Permanent link](https://phage.directory/items/tabula-bioscience-132714488f675100bfcb001edeb54b4f) |
| Tailwind (NCT05616221) | United States | Trial | Completed | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | [Permanent link](https://phage.directory/items/study-to-evaluate-the-safety-phage-kinetics-and-efficacy-of-inhaled-ap-pa02-in-subjects-wi-7424f9cd19985d3fa59fd580d9f43d9f) |
| TecTum Medical Research, Inc. — Hollywood, Florida | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Texas A&M Center for Phage Technology | United States | Supplier | Intake unconfirmed | — | 2026-10-03 | [1](https://cpt.tamu.edu/phage-therapy/) [2](https://cpt.tamu.edu/phage-therapy-projects/) | [Permanent link](https://phage.directory/items/texas-a-m-center-for-phage-technology-293121a347f75ec084333ae1eff41be2) |
| The Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania | United States | Trial site | Historical trial site | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | — |
| The Jamaica Hospital Medical Center — Jamaica, New York | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| The University of Alabama at Birmingham — Birmingham, Alabama | United States | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| The University of Arizona - Banner University Medical Center Tucson Campus - Tucson — Tucson, Arizona | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| The University of Kansas Medical Center — Kansas City, Kansas | United States | Trial site | Historical trial site | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | — |
| The University of Kansas Medical Center / Dept of Medicine — Kansas City, Kansas | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Tilda Research — Irvine, California | United States | Trial site | Historical trial site | 2019–2020 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04191148) | — |
| Tolka AI Therapeutics | United States | Company | Provider-listed inquiry route | — | 2026-10-05 | [1](https://tolka.ai/work/expandedaccess/) [2](https://tolka.ai/contact/) | [Permanent link](https://phage.directory/items/tolka-ai-therapeutics-d949d531b00d5fc4baaabbdb9deea416) |
| Tranquil Clinical Research — Webster, Texas | United States | Trial site | Historical trial site | 2023–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05948592) | — |
| Tufts Medical Center — Boston, Massachusetts | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| UC San Diego IPATH | United States | Center | Case-by-case; Official referral/inquiry route | — | 2026-10-03 | [1](https://idgph.ucsd.edu/research/center-innovative-phage-applications-and-therapeutics/clinical-trial/faq-phage-therapy.html) [2](https://idgph.ucsd.edu/research/center-innovative-phage-applications-and-therapeutics/about/contact.html) [3](https://clinicaltrials.gov/study/NCT06409819) [4](https://clinicaltrials.gov/study/NCT07275905) [5](https://clinicaltrials.gov/study/NCT07280598) [6](https://idgph.ucsd.edu/research/center-innovative-phage-applications-and-therapeutics/_files/ucsd-authorization-to-release-health-information.pdf) | [Permanent link](https://phage.directory/items/uc-san-diego-ipath-22a8c8655ddb5e8587a68da2308819b1) |
| UCONN Health — Farmington, Connecticut | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| UCSF — former BX004 phage trial site | United States | Center | Historical/inactive | — | 2026-10-03 | [1](https://clinicaltrials.ucsf.edu/trial/NCT06998043) [2](https://www.sec.gov/Archives/edgar/data/1739174/000121390026078003/ea0298043-424b3_biomx.htm) | [Permanent link](https://phage.directory/items/ucsf-former-bx004-phage-trial-site-6fcc554c953350f392997d3467dea7e6) |
| Universal Axon - Homestead, LL — Homestead, Florida | United States | Trial site | Historical trial site | 2019–2020 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04191148) | — |
| Universal Axon Clinical Research — Doral, Florida | United States | Trial site | Historical trial site | 2019–2020; 2020–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04191148) [2](https://clinicaltrials.gov/study/NCT04287478) | — |
| University Hospitals Cleveland Medical Center — Cleveland, Ohio | United States | Trial site | Historical trial site | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | — |
| University Hospitals of Cleveland Medical Center — Cleveland, Ohio | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| University Hospitals Rainbow Babies and Children's Hospital — Cleveland, Ohio | United States | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| University of Alabama — Birmingham, Alabama | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| University of Alabama at Birmingham — Birmingham, Alabama | United States | Trial site | Conflicting status (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06998043) | — |
| University of Arkansas for Medical Sciences — Little Rock, Arkansas | United States | Trial site | Conflicting status (trial) | 2022–2024; 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) [2](https://clinicaltrials.gov/study/NCT06998043) | — |
| University of California — San Diego, California | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| University of California Davis Health — Sacramento, California | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| University of California Los Angeles Medical Center - Westwood Clinic — Los Angeles, California | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| University of California San Diego (UCSD) — San Diego, California | United States | Trial site | Not yet recruiting (trial) | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07275905) | — |
| University of California San Diego Medical Center — San Diego, California | United States | Trial site | Historical trial site | 2023–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269134) | — |
| University of California San Francisco — San Francisco, California | United States | Trial site | Conflicting status (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06998043) | — |
| University of California, Los Angeles (UCLA) - Medical Center — Los Angeles, California | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| University of California, San Diego — La Jolla, California | United States | Trial site | Recruiting (trial) | 2022–2025; 2025–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) [2](https://clinicaltrials.gov/study/NCT06409819) | — |
| University of California, San Diego (UCSD) - Antiviral Research Center (AVRC) — La Jolla, California | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| University of California, San Diego (UCSD) - Medical Center — La Jolla, California | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| University of California, San Francisco — San Francisco, California | United States | Trial site | Recruiting (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06938867) | — |
| University of Cincinnati - College of Medicine — Cincinnati, Ohio | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| University of Florida - Jacksonville — Jacksonville, Florida | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| University of Florida — Gainesville, Florida | United States | Trial site | Invitation only (trial) | 2022–2024; 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) [2](https://clinicaltrials.gov/study/NCT06262282) | — |
| University of Florida (UF) - Division of Infectious Disease — Gainesville, Florida | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| University of Iowa — Iowa City, Iowa | United States | Trial site | Historical trial site | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | — |
| University of Maryland Medical Center — Baltimore, Maryland | United States | Trial site | Historical trial site | 2023–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269134) | — |
| University of Maryland School of Medicine — James Doub clinical research | United States | Center | Intake unconfirmed | — | 2026-10-03 | [1](https://www.medschool.umaryland.edu/profiles/doub-james/) [2](https://clinicaltrials.gov/study/NCT05269134) | [Permanent link](https://phage.directory/items/university-of-maryland-school-of-medicine-james-doub-clinical-research-cd3a48c88b34552e857747fd9ea7a50e) |
| University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health — Baltimore, Maryland | United States | Trial site | Active, not recruiting (trial) | 2023–2025 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05182749) | — |
| University of Miami — Miami, Florida | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| University of Michigan — Ann Arbor, Michigan | United States | Trial site | Invitation only (trial) | 2022–2025; 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) [2](https://clinicaltrials.gov/study/NCT06262282) | — |
| University of Minnesota — Minneapolis, Minnesota | United States | Trial site | Recruiting (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06938867) | — |
| University of Minnesota Medical Center — Minneapolis, Minnesota | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| University of North Carolina - Chapel Hill School of Medicine — Chapel Hill, North Carolina | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| University of North Carolina at Chapel Hill — Chapel Hill, North Carolina | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| University of Pennslyvania — Philadelphia, Pennsylvania | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| University of Pittsburgh — Pittsburgh, Pennsylvania | United States | Trial site | Recruiting (trial) | 2026 (estimated)–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT07275905) | — |
| University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| University of South Florida — Tampa, Florida | United States | Trial site | Historical trial site | 2020–2022; 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) [2](https://clinicaltrials.gov/study/NCT05184764) | — |
| University of South Florida/Tampa General Hospital — Tampa, Florida | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| University of Southern California Keck School of Medicine — Los Angeles, California | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| University of Texas Health Science Center at Tyler — Tyler, Texas | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| University of Texas MD Anderson Cancer Center — Houston, Texas | United States | Trial site | Recruiting (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06938867) | — |
| University of Texas Southwestern — Dallas, Texas | United States | Trial site | Historical trial site | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | — |
| University of Texas Southwestern Medical Center — Dallas, Texas | United States | Trial site | Historical trial site | 2020–2023; 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04287478) [2](https://clinicaltrials.gov/study/NCT05453578) | — |
| University of Utah — Salt Lake City, Utah | United States | Trial site | Conflicting status (trial) | 2022–2024; 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) [2](https://clinicaltrials.gov/study/NCT06998043) | — |
| University of Vermont — Burlington, Vermont | United States | Trial site | Invitation only (trial) | 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06262282) | — |
| University of Virginia — Charlottesville, Virginia | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| University of Washington — Seattle, Washington | United States | Trial site | Invitation only (trial) | 2020–2022; 2024–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) [2](https://clinicaltrials.gov/study/NCT06262282) | — |
| University of Washington Medical Center — Seattle, Washington | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| University of Wisconsin — Madison, Wisconsin | United States | Trial site | Historical trial site | 2020–2022 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) | — |
| UPMC — Pittsburgh, Pennsylvania | United States | Trial site | Recruiting (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06938867) | — |
| UPMC Presbyterian — Pittsburgh, Pennsylvania | United States | Trial site | Suspended (trial) | 2023–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05715619) | — |
| UT Health San Antonio phage research collaboration | United States | Research | Research/development | — | 2026-10-03 | [1](https://news.uthscsa.edu/local-grant-boosts-ut-health-san-antonio-scientists-mission-to-advance-phage-therapy/) | [Permanent link](https://phage.directory/items/ut-health-san-antonio-phage-research-collaboration-8644a1aeb85b501b810823a0f22496e3) |
| Vanderbilt University Medical Center — Nashville, Tennessee | United States | Trial site | Conflicting status (trial) | 2020–2022; 2022–2025; 2023–2024; 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04596319) [2](https://clinicaltrials.gov/study/NCT05453578) [3](https://clinicaltrials.gov/study/NCT05616221) [4](https://clinicaltrials.gov/study/NCT06998043) | — |
| Velocity Clinical Research — Mobile, Alabama | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Virginia Commonwealth University (VCU) — Richmond, Virginia | United States | Trial site | Historical trial site | 2023–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05616221) | — |
| Wake Forest University Health Sciences — Winston-Salem, North Carolina | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05184764) | — |
| Washington University in St Louis — St Louis, Missouri | United States | Trial site | Recruiting (trial) | 2025–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06559618) | — |
| Washington University School of Medicine — SCI bacteriuria trial | United States | Center | Official referral/inquiry route | — | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06559618) | [Permanent link](https://phage.directory/items/washington-university-school-of-medicine-sci-bacteriuria-trial-8d97021ab4ca5477b4edf58201954927) |
| Weill Cornell Medicine — New York, New York | United States | Trial site | Recruiting (trial) | 2025–2026 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT06938867) | — |
| William Beaumont Hospital — Royal Oak, Michigan | United States | Trial site | Historical trial site | 2023–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269134) | — |
| WPP-201 (NCT00663091) | United States | Trial | Completed | 2006–2008 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT00663091) | [Permanent link](https://phage.directory/items/a-prospective-randomized-double-blind-controlled-study-of-wpp-201-for-the-safety-and-effic-04af88763fe55bf68e78fba222f27646) |
| WVU Medicine JW Ruby Memorial Hospital — Morgantown, West Virginia | United States | Trial site | Historical trial site | 2023–2027 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05269134) | — |
| Yale New Haven Hospital — New Haven, Connecticut | United States | Trial site | Historical trial site | 2021–2023 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04684641) | — |
| Yale North Haven Medical Center- Winchester Center for Lung Disease — North Haven, Connecticut | United States | Trial site | Historical trial site | 2022–2025 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05453578) | — |
| Yale Phage Therapy Program | United States | Center | Case-by-case; Official referral/inquiry route | — | 2026-10-03 | [1](https://phage.yale.edu/faqs) [2](https://phage.yale.edu/therapy) [3](https://clinicaltrials.gov/study/NCT04684641) | [Permanent link](https://phage.directory/items/yale-phage-therapy-program-cb12c9f5d1955a75ad1272ea4a0f35ff) |
| Yale University — New Haven, Connecticut | United States | Trial site | Historical trial site | 2022–2024 | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT05010577) | — |
| Kinzbio personalized phage supply | Uruguay | Supplier | Official referral/inquiry route | — | 2026-10-03 | [1](https://www.gub.uy/ministerio-salud-publica/institucional/normativa/ordenanza-n-1162024-autorizacion-para-practica-terapia-personalizada) [2](https://www.gub.uy/ministerio-salud-publica/sites/ministerio-salud-publica/files/2025-05/Ord_1162_2024.pdf) [3](https://www.kinzbio.com/) | [Permanent link](https://phage.directory/items/kinzbio-personalized-phage-supply-473aeb03804c5ca0bf54936eec84650b) |
| Bacteriophage Therapy in Tonsillitis (NCT04682964) | Uzbekistan | Trial | Active, not recruiting | 2020–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04682964) | [Permanent link](https://phage.directory/items/bacteriophage-therapy-in-tonsillitis-5d8c6f3294ad54ba80fdab800c0c567d) |
| Tashkent Pediatric Medical Institute — Tashkent | Uzbekistan | Trial site | Active, not recruiting (trial) | 2020–2028 (estimated) | 2026-10-03 | [1](https://clinicaltrials.gov/study/NCT04682964) | — |